Oxidative stress and inflammatory responses sustained for a long period of time cause many diseases. A proinflammatory cytokine, tumor necrosis factor (TNF-), plays a pivotal role in the pathogenesis of chronic and autoimmune diseases. The present review, supplemented by hitherto unpublished data of the authors and their coworkers, shows that the intake of polyphenols contained in natural sources, such as hydroxytyrosol, tyrosol, oleuropein (olives), naringin and hesperidin (Citrus fruits), resveratrol, procyanidins or oligomeric procyanidin (grapes or grape seed extracts), (-)-epigallocatechin gallate (green tea) and quercetin (grapes, green tea) etc., are able to modulate chronic inflammatory diseases, such as type 2 diabetes, rheumatoid arthritis, inflammatory bowel disease, and affect the formation and interaction of advanced glycation end products with their respective receptors. Furthermore, potent activities of fermented grape marc, prepared as a fine lyophilized powder from fresh skin and seeds of a Japanese grape strain (Koshu) and then fermented with Lactobacillus plantarum, are described. Finally, the bioavailability of representative polyphenols will be discussed.
INTRODUCTION
The production of reactive oxygen species (ROS), cytokines and chemokines at inflammatory sites is a pivotal event in the progression of many diseases. Among those substances, tumor necrosis factor (TNF-) is a proinflammatory cytokine for inducing acute and chronic inflammatory responses. TNF-is produced by various types of cells, especially monocytes/macrophages, which infiltrate inflammatory sites, and is implicated in the pathogenesis of a variety of chronic inflammatory diseases, such as type 2 diabetes, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD). In rheumatoid synovial tissue, activated mast cells also produce TNF-, interleukin (IL)-6 and IL-8. Furthermore, the interaction of advanced glycation end products (AGEs) with respective receptors for AGEs (RAGE) induces augmented TNF-production and subsequently triggers agerelated diseases. Therefore, regulators of TNF-production may be beneficial in preventive and therapeutic treatments for inflammatory diseases.
Flavonoids are well-known as pharmacologically active compounds with antioxidant and anti-inflammatory activities [1] . The term "flavonoids" generically covers more than 8000 compounds, which have a C 6 -C 3 -C 6 carbon (A-C-B rings) structure and are widely distributed in the plant kingdom. While flavonoids usually occur as glycosides, they are based on the fundamental chemical structure of the corresponding aglycones having only the ring structure, e.g. into flavones, flavonols, flavanones, flavanonols, isoflavones, catechins, chalcones, anthocyanidins, proanthocyanidins, and *Address correspondence to this author at the Laboratory of Pharmacognosy, Faculty of Pharmacy, Iwaki Meisei University, 5-5-1 Chuodai-Iino, Iwaki, Fukushima 970-8551, Japan; E-mail: kiichi-k@iwakimu.ac.jp others. Flavonoids are functional constituents of many fruits and vegetables. The present review focuses on inhibitory effects of representative flavonoids and other components, present in green tea, grapes, oranges, olives, and vegetables, on obesity and type 2 diabetes, RA, IBD and AGEs.
INHIBITORY EFFECTS ON OBESITY AND TYPE 2 DIABETES
For a long period of time the adipose tissue was considered as a simple fat accumulation. Nowadays it is fascinating to progressively discover its involvement in the dysregulation of hormones, inflammation and the immune system. Recently it became known that adipokines and cytokines are involved in controlling the regulation of appetite and energy balance. The so-called metabolic syndrome is associated with dysfunctional adipose tissue, which most likely is a consequence of the enlargement of adipocytes. Chronic inflammation in adipose tissue results in reduced secretion of adiponectin and increased secretion of inflammatory cytokines such as TNF-, IL-6, IL-8 and monocyte chemoattractant protein (MCP)-1. A proinflammatory state in the adipose tissue leads to an impaired inhibitory effect of insulin on the release of free fatty acid (FFA) by lipolysis and to endothelial dysfunction that clearly promotes cardiovascular diseases and type 2 diabetes. The endothelial dysfunction occurring in type 2 diabetes is the result of the effects of the inflammatory cytokine TNF-and TNF--relating signaling, including the expression of MCP-1 and adhesion molecules, which further exacerbates vessel inflammation and oxidative stress [2] .
Obesity is also characterized by a low grade inflammation. Toll-like receptor 4 (TLR4), a molecule essential for innate immunity, increases in skeletal muscle of obese and type-2 diabetic humans [3] . Activation of the CD14/TLR4 complex with endotoxic lipopolysaccharide (LPS), a ligand of TLR4, and/or fatty acids triggers the development of obesity, inflammation, insulin resistance, type 2 diabetes and atherosclerosis [4, 5] . The anti-inflammatory properties of flavonoids have recently been investigated in order to establish and characterize their potential utility as preventive and therapeutic agents.
Citrus Flavonoids
Treatment with Citrus flavonoids, such as hesperidin and naringin, has recently been shown to decrease LPS-induced TNF-production and to inhibit endotoxin shock in galactosamine-sensitized mice or infected mice [6] [7] [8] . There is an interesting report that intake of fresh grapefruit by obese patients for 12 weeks significantly reduces weight loss [9] . An increasing number of studies demonstrates that Citrus flavonoids offer some protection against the early stage of diabetes mellitus and the development of complications. Supplementation with hesperidin and naringin reduces blood glucose levels, and upregulates hepatic glucokinase activity and the glycogen concentration in male C57BL/KsJ-db/db mice, a mouse model of type 2 diabetes, which are fed a normal diet for two weeks and subsequently either AIN-76 (a standard laboratory diet without supplements) or AIN-76 supplemented with flavonoids [10] . Administration of naringin to streptozotocin (STZ)-induced hyperglycemic rats decreases dose-dependently plasma levels of glucose, hydrogen peroxide and thiobarbituric acid-reactive substances, and increases the insulin concentration and antioxidant enzyme activities [11] . Treatment of low-density lipoprotein (LDL) receptor-null mice with naringenin, an aglycone of naringin, for 4 weeks 1) induces increased hepatic fatty acid oxidation; 2) prevents sterol regulatory element-binding protein 1c-mediated lipogenesis; 3) decreases hepatic cholesterol and cholesterol ester synthesis; 4) lowers both VLDL-derived and endogenously synthesized fatty acid levels; and 5) improves overall insulin sensitivity and glucose tolerance [12] . Treatment of high-fat diet fed mice with naringenin for 6 months decreases atherosclerosis development, liver triglycerides, and cholesterol ester mass [13] . Intake of dietary hesperidin (10 g/kg diet) decreases blood glucose levels by altering the activity of glucose-regulating enzymes, and normalizes lipid and adiponectin levels, but does not change bone parameters in STZ-induced marginal type-1 diabetic rats [14] . Citrus flavonoids, such as hesperetin and naringenin, inhibit TNF--stimulated secretion of FFA from mouse adipocytes through activation of nuclear factor (NF)-B and extracellular signal-regulated kinase (ERK) pathways [15] .
Grape Polyphenols
Grapes contain numerous polyphenols, including the stilbene resveratrol, the flavanol quercetin, catechins, and anthocyanins, all of which have shown a potential for reducing hyperglycemia, improving -cell function, and protecting against -cell loss [16] . Current studies show that grape polyphenols modulate several markers of vascular risk, such as endothelial dysfunction, oxidative stress, inflammation, and insulin resistance in the pathogenesis of type 2 diabetes. Pretreatment of macrophages with grape seed extract (GSE) attenuates LPS-induced production of inflammatory cytokines, such as TNF-, IL-6 and IL-1 and chemokines, such as IL-8 and interferon-inducible protein-10 (IP-10). GSE also modulates LPS-mediated activation of mitogen activated protein kinase (MAPK), NF-B and activator protein-1 (AP-1) [17] . In co-cultures of murine white adipocytes and macrophages the production of TNF-, MCP-1 and plasminogen activator inhibitor-1 is markedly increased. Treatment of white adipocytes with oligomeric grape seed polyphenol attenuates the dysregulated production of adipokines [18] . Treatment of human adipocytes and macrophage-like THP-1 cells with grape seed procyanidin extracts (GSPE) reduces the expression of IL-6 and MCP-1 after an inflammatory stimulus [19] . GSE has inhibitory activities on pancreatic lipase and lipoprotein lipase of 3T3-L1 adipocytes [20] . Sustained consumption of Chardonnay GSE improves plasma glucose levels and insulin resistance values in hamsters [21] . GSE supplement reduces the weight gain and blood lipid levels in C57BL/6 mice fed high-fat diets [22] . In Zucker fa/fa rats fed a high-fat diet supplemented with procyanidins from grape seed (3.45 mg/kg fed), plasma TNF-, but not IL-6, levels and plasma C-reactive protein (CRP) levels decrease compared with those of controls fed the high-fat diet alone [23] . Dietary supplementation with red wine polyphenol extract (Provinols TM ) improves metabolic markers by reducing plasma glucose levels, circulating triglyceride and total cholesterol as well as LDL in Zucker fa/fa rats [24] . Intake of GSE at a dose of 600 mg/day for 4 weeks improves several markers of inflammation, glycemia and oxidative stress in obese patients with type 2 diabetes [25] . Likewise, an active role of anthocyanins in preventing the progress of cardiovascular and neurodegenerative diseases, obesity, inflammation, and cancer has been suggested.
Grape marc contains a high amount of oleanolic acid, a pentacylic triterpene, ranging from 4 to 11g/100g, and supplementation of a high-fat diet with 0.05% oleanolic acid to rats induces a decrease in plasma levels of triglycerides and phospholipids and down-regulates gene expression relating to neogluconeogensis and production of inflammatory cytokines [26] . Chronic treatment of mice fed a high-fat diet with oleanolic acid for 15 weeks reduces glucose tolerance, and decreases body weight, visceral adiposity, blood glucose, and plasma lipids relative to controls fed a high-fat diet alone. This treatment also elevates plasma leptin levels and decreases plasma ghrelin levels [27] . Resveratrol (trans-3,4',5-trihydroxystilbene) is a natural activator of sirtuin 1 (SIRT1), an NAD(+)-dependent histone deacetylase, and links nutrient availability and energy metabolism [28] [29] [30] [31] [32] . Enhanced SIRT1 activity decreases blood glucose levels, improves insulin sensitivity, increases mitochondrial numbers and function, decreases adiposity, improves exercise tolerance and potentially lowers body weight. However, the low bioavailability of resveratrol and its interaction with multiple molecular targets still remain a problem. Sustained supplementation of fermented grape marc (FGM), prepared as a fine powder which fresh marc (skin and seeds) of Vitis vinifera Koshu for white wine was ground, incubated with Lactobacillus plantarum and lyophilized after pasteurization, for 4 weeks decreased the markers of weight gain, abdominal fat, blood glucose, and triglycerides in KK-A y mice. Conversely, treatment of KK-A y mice with FGM increased plasma adiponectin levels Fig. (1) . Supplementation with FGM may provide a potential mechanism for the prevention of cardiovascular and metabolic alterations associated with obesity.
Fig. (1).
Effects of FGM on weight gain, abdominal fat, blood glucose, triglyceride, and adiponectin as type 2 diabetes markers in KK-A y mice. KK-A y mice were fed normal diet with or without supplementation of FGM (300 mg/day) for 4 weeks. (unpublished data by T. Tominaga and coworkers).
Green Tea and Catechins
Green tea is naturally rich in a group of antioxidants known as catechins since its production involves little processing and fermentation of the leaves and buds of the tea plant (Camellia sinensis), and has been suggested to have a number of potential health benefits in cardiovascular disease, cancer prevention, glucose homeostasis and dental health [33] . Many of the beneficial effects of green tea are related to the content of its catechins, particularly (-)-epigallocatechin-3-gallate (EGCG). The efficacy of green tea and EGCG has been demonstrated in cell cultures and animal models of obesity, where adipocyte differentiation and proliferation, lipogenesis, fat mass, body weight, fat absorption, plasma levels of triglycerides, free fatty acids, cholesterol, glucose, insulin and leptin were lowered, and -oxidation and thermogenesis were increased [34] . In mice fed a highfat diet (60% energy as fat), supplementation with dietary EGCG (3.2 g/kg diet) for 18 weeks reduces body weight gain, the percentage of body fat, and visceral fat weight compared with mice without EGCG treatment. Treatment with EGCG improves insulin resistance, plasma cholesterol levels, and MCP-1 concentrations, and also decreases liver weight, liver triglycerides, and plasma alanine aminotransferase concentrations in high-fat-fed mice. Thus, long-term treatment with EGCG can attenuate the development of obesity, symptoms associated with the metabolic syndrome, and fatty liver [35] . The majority of human epidemiological and intervention studies suggests beneficial effects of EGCG-rich green tea or green tea extracts on weight management, glucose control and cardiovascular risk factors [36] . Although dozens of disease-specific molecular targets are only affected by concentrations of EGCG that are far above the levels caused by either drinking green tea or consuming moderate doses of green tea extract-based dietary supplements in animal experiments, well-designed and double-blind controlled clinical studies demonstrate the efficacy of green tea extracts and purified EGCG products in patients [37] .
In cultured cells, such as Hepa 1-6, and 3T3-L1 cells, EGCG induces an increase of AMP-activated protein kinase (AMPK ) activity and of the phosphorylation of the downstream target acetyl-CoA carboxylase. The gallocatechin moiety and a galloyl residue act as an AMPK activator. Phosphorylation of LKB1, which is a tumor-suppressor protein and a major AMPK-kinase, is increased by EGCG treatment, and its increase is reversed by treatment with catalase, suggesting that reactive oxygen species are involved in the EGCG-induced activation of the LKB/AMPK pathway. Oral administration of EGCG (200mg/kg body weight) to BALB/c mice induces an increase in AMPK activity in the liver concomitant with a significant increase in AMPK and acetyl-CoA carboxylase phosphorylation [38] .
Other Flavonoids
Recent studies show that some flavonoids modulate several mediators of inflammatory response. Flavonoids inhibit the expression of proinflammatory genes, such as cytokines, chemokines or adhesion molecules, the expression of inducible nitric oxide synthase (iNOS) isoforms, and the production of other mediators, such as prostanoids and leukotrienes [39, 40] . Treatment with quercetin decreases plasma levels of oxidized LDL and TNF-in overweight patients with the apoE3 and apoE4 genotypes [41] , and induces a progressive, dose-dependent and sustained reduction in blood pressure in several models, such as spontaneously hypertensive rats, Nnitro-L-arginine methyl ester-treated rats, deoxylcorticosterone acetate-salt hypertensive rats, two-kidney one-clip Goldblatt rats, rats with aortic obstruction, Dahl salt-sensitive hypertensive rats and obese-Zucker rats [42] . Quercetin also has anti-hypertensive effects, anti-thrombotic and antiinflammatory effects in humans [43] .
The flavone luteolin inhibits LPS-induced TNF-release and the activation of the NF-B pathway in macrophages. Treatment of 3T3-L1 adipocytes for 24 h enhances Akt2 phosphorylation in an insulin-stimulated state, leading to an increased uptake of glucose in response to insulin. Luteolin treatment decreases mRNA levels of TNF-, IL-6 and MCP-1, while it increases the gene expression of adiponectin and leptin and enhances the transcription of peroxisome proliferator-activated receptor (PPAR ) in 3T3-L1 adipocytes [44] . An interaction of adipocytes and macrophages contributes to the development of insulin resistance in obese adipose tissues. In co-cultures of adipocytes and macrophages the presence of luteolin decreases the production of inflammatory mediators, and luteolin inhibits the phosphorylation of JNK in activated macrophages [45] .
INHIBITORY EFFECTS ON RHEUMATOID AR-THRITIS (RA)
RA is characterized by chronic inflammation of synovial joints. The excessive proliferation and migration of synoviocytes are well-characterized by phenomena that play key roles in the pathophysiology of RA. TNF-is implicated in the pathology of a variety of chronic autoimmune diseases, particularly RA. Since the discovery of the role of TNF-in the pathogenesis of the disease in the late 1990s, treatment outcomes in RA have been improved considerably by the use of biological therapies using the first marketed TNF--related drugs, such as monoclonal anti-TNF antibodies (Infliximab and Adalimumab) and soluble TNF receptor (Etanercept). About 60% of the patients who do not benefit from standard nonbiological treatments for TNF-related diseases respond to TNF antagonists. Less than half of responding patients achieve a state of complete remission of the respective disease. Despite the substantial clinical efficacy of TNF antagonist therapies, some patients respond poorly to such agents. For these patients other therapies involving new strategies for the regulation of TNF-production are required.
Activated mast cells in rheumatoid synovial tissue also produce TNF-, IL-6 and IL-8, and adjacent cell types are also involved in the pathogenesis of the disease. Rheumatoid synovial fibroblasts produce matrix metalloproteinases (MMPs) and cause joint destruction. Flavonoids have inhibitory effects on the acute and chronic inflammatory responses caused by TNF- [1] . Several studies with plant flavonoids suggest that even for patients poorly responding to anti-TNF antagonists there still remains the possibility that therapies with flavonoids and other natural antioxidants may ameliorate their condition.
Olive Phenolic Hydroxytyrosol
The olive fruit and compression-extracted olive oil is the essential component of the Mediterranean diet, a nutritional regimen gaining ever-increasing renown for its beneficial effects on inflammation, cardiovascular disease, and cancer. Olive oil has a wide range of therapeutic and culinary applications. The active components of olive oil include oleic acid, phenolic constituents, and squalene. A unique characteristic of olive oil is its enrichment in oleuropein, a member of the secoiridoid family, which converts to hydroxytyrosol after sequential digestion by -glycosidase and esterase. The phenolic compounds are hydroxytyrosol, tyrosol and oleuropein, which occur in highest levels in virgin olive oil, and have demonstrated antioxidant activity [46] . Antioxidants are believed to be responsible for a number of the biological activities of olive oil [47] . Hydroxytyrosol, which is abundant in the aqueous fraction of olive pulp, is a simple phenolic compound and possesses a marked antioxidant activity. In combination with glucosamine, olive vegetation water containing hydroxytyrosol inhibits LPS-induced release of nitric oxide and TNF-in BALB/c mice [48] and in human monocytic THP-1 cells [49] . Hydroxytyrosol-20 (HT20), a preparation containing 20% hydroxytyrosol, significantly decreased clinical scores in collagen induced arthritis (CIA) mice when given orally at a dose of 100 mg/kg HT-20 after the first immunization, although its efficacy was weaker than that of 1 mg/kg prednisolone Fig. (2) . 
Citrus Hesperidin and Other Compounds
Successive oral administration of hesperidin causes a decreased incidence of clinical scores in CIA mice treated with hesperidin either after the secondary antigenic stimulation or from the logarithmic phase of the development of CIA onwards [50] . Oral administration of hesperidin significantly attenuates secondary paw swelling and reduces the arthritis index in rats with adjuvant arthritis. In a doubleblind and placebo-controlled trial test, RA patients are given beverages containing 3 g Hsp-G or placebo every morning for the duration of the trial, and receive standard therapy from a physician every 4 weeks. As a result, the condition of 3 of 9 patients in the Hsp-G group improves, as compared to only 1 of 10 patients in the placebo group, suggesting that food containing Hsp-G would be effective for improving the quality of life of RA patients if they receive a combination therapy of standard anti-rheumatoid drugs and Hsp-G [51]. Intraperitoneal treatment of CIA mice with the Citrus polymethoxy flavonoid nobiletin suppresses mRNA expression of aggrecanase-1/a disintegrin, MMP with thrombospondinlike motifs (ADAMTS)-4 and aggrecanase-2/ADAMTS-5 in the joint tissues [52] . Nobiletin suppresses the reduction of whole bone mineral density in ovariectomized mice by 61%, which is comparable to or exceeding the efficacy of 17 -estradiol. Intraperitoneal injection of nobiletin into CIA mice leads to a marked decrease in the incidence of arthritis [53].
Green Tea and Catechins
Catechins from green tea, particularly those containing a gallate ester, inhibit the in vitro degradation of human cartilage proteoglycan and type II collagen [54] . Oral administration of catechin to rats with adjuvant arthritis leads to significant decreases in secondary inflammatory paw swelling, pain response, and polyarthritis. Catechin also suppresses the production of TNF-, IL-1 , and prostaglandin (PG) E 2 [55] . Treatment with EGCG, a representative catechin in green tea, ameliorates clinical symptoms and reduces histological scores in mice, in which arthritis has been induced by injecting a cocktail of monoclonal antibodies against collagen. EGCG suppresses the TNF--induced production of MMP-1 and MMP-3 in RA synovial fibroblasts, and inhibits mitogen activated protein kinases (MAPKs) and activator protein-1 (AP-1) [56] . Furthermore, EGCG reduces the generation of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells, bone resorption activity, and osteoclastspecific gene expression [57] . Finally, EGCG inhibits IL-1 -induced IL-6 production and trans-signaling in RA synovial fibroblasts by inducing alternative splicing of gp130 mRNA, resulting in enhanced soluble gp130 production. Results from in vivo studies using a rat adjuvant-induced arthritis model show specific reduction of IL-6 levels in the serum and joints of EGCG-treated rats by 28% and 40%, respectively, with concomitant amelioration of the arthritis. EGCG decreases membrane-bound gp130 protein expression in the joint [58] . The therapeutic effect of EGCG is also demonstrated in rats with CIA by marked reduction of severity, macrophage infiltration, and oncostatin-induced CCL2-synthesizing osteoblasts [59].
Grape Polyphenols and Others
Intraperitoneal treatment of mice with GSPE attenuates the severity of CIA in a dose dependent manner and reduces the histological scores for synovial inflammation, cartilage erosion, bone erosion, and the number of TRAP+ osteoclasts [60] . GSPE treatment reduces the numbers of TNF--or IL-17-producing cells in synovial tissue. Recently it was found that daily intake of FGM significantly ameliorates the severity of CIA in DBA/1 mice Fig. (3A) , and reduces the histologic scores [61].
Quercetin and Other Flavonoids
Quercetin is one of the representative flavonoids possessing potent biological and pharmacological activities. Human secretary phospholipase A2 (PLA2) is a lipolytic enzyme of the arachidonic acid cascade, and its activation induces inflammation by metabolic eicosanoids. Quercetin, kaempferol, galangin but not naringenin show good activity with respect to the inhibition of PLA2 [62] . Daily oral administration of quercetin to mice with CIA significantly attenuates the severity of clinical scores and reduces histologic scores Fig. (3B) [61].
Intake of vitamin E and quercetin modulates inflammatory responses of CIA mice [63] . The flavone luteolin inhibits the proliferation of synovial fibroblasts in rats with CIA. Treatment with luteolin decreases the secretion of MMP-1 and MMP-3 and the expression of IL-6, IL-8, IL-15, and TGF-, and inhibits the proliferation and partially blocks the pathogenic function of synovial fibroblasts [64] . Fisetin inhibits IL-1 -induced proliferation of fibroblast-like synovial cells and decreases IL-1 -induced production of inflammatory cytokines (TNF-, IL-6, IL-8, MCP-1 and vascular endothelial growth factor (VEGF). Treatment with fisetin reduces the incidence and severity of CIA [65] . Fig. (3) . Inhibitory effects of quercetin (A) and FGM (B) on clinical scores of CIA mice. Male DBA-1 mice were immunized twice with chicken type-II collagen, and orally given either quercetin (100 mg/kg/day) or FGM (100 mg/kg/day) from day 0 after the secondary immunization (on day 21 in the figure). CIA controls (closed circle), quercetin-treated (open circle) and FGM-treated (closed square). *P<0.05, **<0.01, and ***P<0.001. (unpublished data by K. Kawaguchi and coworkers).
Treatment with Detralex, a purified micronized flavonoid fraction, in combination with methotrexate amplifies the beneficial effects of methotrexate, which results in a more significant reduction in hind paw swelling, arthritic scores and serum concentrations of nitrite/nitrate in rats with adjuvant arthritis [66] . RA patients poorly responding to anti-TNF antibody therapies might benefit from a treatment based on a combination of non-biological agents and flavonoids.
INHIBITORY EFFECTS ON INFLAMMATORY BOWEL DISEASE (IBD)
IBD, including Crohn's disease and ulcerative colitis, is a chronic inflammatory gastrointestinal autoimmune condition with an inappropriate immune response. In IBD, the epithelial barrier function is impaired, contributing to diarrhea by a leak flux mechanism and perpetuating inflammation by an increased luminal antigen uptake. The barrier of the intestinal epithelium is composed of the apical enterocyte membrane and the epithelial tight junctions, and can be affected by tight junction alterations, induction of epithelial apoptosis and appearance of gross lesions like erosions or ulcers as well as by accelerated transcytotic antigen uptake. As far as regulation is concerned, Th1 cytokines like TNF-and interferon-(IFN-) are important for Crohn's disease, while Th2 responses are dominated by IL-13 and TNF-in ulcerative colitis [67] . Thus, anti-inflammatory remedies with anti-TNF-antibodies are most effective in ameliorating active IBD and concomitantly repairing barrier function. Anti-TNF-antibodies induce apoptosis in immune cells, which in turn leads to a lower number of immune cells, which are able to release cytokines, so that a lower amount of cytokines leads to less inflammation. On the other hand, other agents can also affect barrier function. Dietary polyphenols from fruits and vegetables can strengthen the epithelial barrier [68].
Olive Oil Components
Phenolic compounds in olive oil are absorbed from the intestine and exert a significant antioxidant effect in vivo [69] . Compared with normal tissue, the colonic mucosa of patients suffering from predisposing cancer or inflammatory conditions, such as ulcerative colitis and Crohn's disease, generates higher quantities of reactive oxygen species. Antioxidant polyphenolic compounds in olive oil are potent inhibitors of free radicals generated by the faecal matrix [70] . In rats with dextran sulfate sodium (DSS)-induced colitis an olive-oil based diet induces a lower colonic inflammatory response than a soy bean-oil diet. This beneficial effect increases by incorporation of (n-3) polyunsaturated fatty acids into the diet. The combination decreases colonic levels of TNF-and leukotriene B4 compared with those in rats with colitis supplemented with fish oil alone [71] . Extra-virgin olive oil contains an abundance of phenolic components including simple phenols (hydroxytyrosol, tyrosol), aldehydic secoiridoids, flavonoids and lignans (acetoxypinoresinol, pinoresinol), and possesses anti-inflammatory, anti-proliferative and anti-apoptotic effects. Compared to sunflower oil, the supplementation of extra-virgin olive oil to C57BL/6 mice with DSS-induced colitis induces a lower cytokine production. Conversely, the expression of cyclo-oxigenase-2 (COX-2) and iNOS is lower in extra-virgin olive oil-fed mice than in sunflower oil-fed mice [72].
Green Tea and Black Tea
DSS-treated BALB/c mice develop severe colitis as shown by bloody diarrhea, weight loss and pathological manifestations. Green tea polyphenols improve diarrhea and colon lesions, and increase body weights. Colon lengths are decreased due to mucosal inflammation in DSS-treated animals, but a therapy with green tea polyphenols normalizes this pathological finding. The blood level of reduced glutathione is decreased in DSS-treated mice and returns to normal when treated with antioxidants. Serum amyloid A (acute phase protein) and TNF-was increased in DSStreated animals and return to lower values in the course of the treatment. The actin cytoskeleton is distorted and fragmented in the mucosa of DSS-treated mice and improves with the antioxidant therapy [73] . Administration of green tea polyphenols in water to IL-2-deficient mice for 6 weeks improves colitis as demonstrated by histologic scores and wet colon weights, and lowers the spontaneous release of TNF-and IFN-in cultures of colon and lamina propria (LP) lymphocytes from the mice treated with green tea polyphenols [74] . Many of these biological effects of green tea are mediated by EGCG, the major polyphenol present therein. Caffeine also suppresses LPS-induced apoptosis of hepatocytes in D-galactosamine-sensitized rats [75] . EGCG, but not catechin or ethyl gallate, abrogates high mobility group box 1 (HMGB1) release in macrophage/monocyte cultures after LPS stimulation, and intraperitoneal injection of EGCG protects mice against lethal endotoxemia [76] . In rats with trinitrobenzene sulphonic acid (TNBS)-induced colitis, treatment with green tea extracts attenuates diarrhea and loss of body weight. This is associated with a remarkable amelioration of the disruption of the colonic architecture and a significant reduction of the production of colonic myeloperoxidase (MPO) and TNF-[77].
Thearubigin is the major polyphenol of black tea and has potent anti-inflammatory and anti-oxidant activities. In mice with TNBS-induced colitis, intestinal lesions are associated with neutrophil infiltration, increased serine protease activity and high levels of malondialdehyde. Pretreatment of mice with thearubigin (40 mg/kg/day, intragastrically, for 10 days) ameliorates the appearance of diarrhea and the disruption of the colonic architecture, and reduces the levels of nitric oxide (NO) and O 2 -and the NF-B activation in colonic mucosa [78] . Theaflavin-3,3'-digallate is also one of the potent anti-oxidant polyphenols in black tea, and can down-regulate the NF-B activation. Oral administration of theaflavin-3,3'-digallate (5 mg/kg, daily, intragastrically) improves TNBSinduced colitis and was associated with decreased mRNA and protein levels of TNF-, IL-12, IFN-and iNOS in colonic mucosa. Pretreatment with theaflavin-3,3'-digallate inhibits TNBS-induced increases in nuclear localization of NF-B, cytosolic IKK activity and preserved I B in colon tissue [79].
Grape Polyphenols and Others
GSPE exerts a beneficial anti-inflammatory effect in the acute phase of TNBS-induced colitis in rats; 1) downregulation of some mediators involved in the intestinal inflammatory response, 2) inhibition of inflammatory cell infiltration and oxidative damage, 3) promotion of damaged tissue repair to improve colonic oxidative stress, 4) a decrease in the production of the proinflammatory cytokine IL-1 , and 5) an increase in production of the anti-inflammatory cytokines IL-2 and IL-4 [80] . Recently it was found that FGMtreatment of mice with DSS-induced colitis dose-dependently ameliorated colonic oxidative stress, as demonstrated by the colonic length, and down-regulates TNF-as well as IL-1 in the colon Fig. (4) [81].
Resveratrol has anti-inflammatory, antioxidant, antitumor and immunomodulatory activities. Treatment of TNBS-induced colitis mice with resveratrol (5-10 mg/kg/ day) reduces the degree of colonic injury, the index of neutrophil infiltration and the levels of the IL-. Resveratrol reduces PGD 2 levels and the COX2 expression in the colitis mice [82] . Treatment of DSS-induced colitis mice with resveratrol attenuates overall clinical scores as well as various pathological markers of colitis, and reverses the colitisassociated decrease in body weight and increased levels of serum amyloid A, TNF-, IL-6, and IL-1 . In mice with DSS-induced colitis, which is associated with a decrease in SIRT1 gene expression and an increase in NF-B activation, resveratrol also suppresses the expression of COX-2 [83]. Fig. (4) . Inhibitory effects of FGM on the colon length and colon TNF-levels in colitis mice. BALB/c mice were given either water (control) or 5% dextran sulfate sodium solution for 7 days. (unpublished data by T. Tominaga and coworkers).
Piceatannol (3,3',4',5-tetrahydroxy-trans-stilbene), a polyphenol found in grapes, is a protein kinase inhibitor that modifies multiple cellular targets, exerting immunosuppressive and anti-tumorigenic activities in several cell lines. Treatment of mice with DSS-induced colitis with piceatanol ameliorates the disruption of the colonic architecture, reduces colonic MPO activity, and decreases the production of inflammatory mediators such as NO, PGE2, and of proinflammatory cytokines [84].
Apple Flavonoids and Others
Apples and their products contain high amounts of polyphenols possessing diverse biological activities that contribute to beneficial health effects. Oral administration of apple polyphenols attenuates the DSS-induced mortality rate and decreased body weight loss, and also prevented the body weight loss of mice with oxazolone-induced colitis. Apple polyphenols increase the proportions of TCR T cells and TCR -CD8 T cells in intraepithelial lymphocytes (IEL), suppress IFN-in stimulated IEL, and inhibit IL-8 secretion by intestinal epithelial cells stimulated with phorbol myristate acetate [85] . Apple juice extract, AE04 g/mL), inhibits the expression of NF-B-regulated proinflammatory genes (TNF-, IL-1 , CXCL9, CXCL10), inflammatory relevant enzymes (COX-2, CYP3A4), and transcription factors (STAT1, IRF1) in LPS/IFN-stimulated MonoMac6 cells without significant effects on the expression of house-keeping genes. Major compounds of AE04 are flavan-3-ol dimer procyanidin B 2 , which is mainly responsible for the anti-inflammatory activity, dihydrochalcone aglycone phloretin and dimeric flavan-3-ol procyanidin B 1 [86] . After 3 months feeding of 7.6% lyophilized apples obtained from two cultivars (Golden Delicious and Marie Ménard), rats fed Marie Ménard apples (high in polyphenols) had reduced MPO activity, reduced gene expression of COX-2 and i-NOS in the colon mucosa and less diarrhea, compared with control rats. Cell proliferation in the colon mucosa was reduced significantly by feeding Golden Delicious apples (low in polyphenols). In rats fed Marie Ménard lyophilisate a downregulation of the pathways of PG synthesis, MAPKs signaling and TNF--NF-B was detected by gene expression profiling of the colon [87] .
The anti-inflammatory properties of hesperidin are due to its inhibition of different pro-inflammatory mediators, TNFand arachidonic acid derivatives [5, 88] . Treatment with hesperidin induces decreases in the disease activity index, the MPO activity, the malondialdehyde content, and the serum level of IL-6 in mice with DSS-induced colitis [89] , and also reduces the colonic MPO activity in rats with TNBSinduced colitis [90] .
In assay systems in vitro, chrysin and ellagic acid inhibit NF-B activiation, whereas genistein and resveratrol increase it. Chrysin reduces IL-1 -induced I B-phosphorylation, whereas ellagic acid increases it. Ellagic acid, genistein and EGCG reduce IL-1 -induced IL-8 secretion, while resveratrol promotes the secretion. Chrysin also diminishes IL-8 secretion, suggesting that polyphenols can modulate the NF-B activation pathway in the intestine. 
INHIBITORY EFFECTS ON ADVANCED GLYCA-TION AND CROSS-LINKING
AGEs are formed by the non-enzymatic reaction between reducing sugars and free amino groups of proteins. AGEs are present in 2-microglobulin-amyloid fibrils of dialysisrelated amyloidosis, a hallmark of which is an accelerated bone resorption around amyloid deposits. Accumulation of insoluble protein deposits and their cross-linking by AGEs in the brain is a feature of aging and neurodegeneration, especially in Alzheimer's disease. Advanced glycation due to hyperglycemia has been shown to correlate with the severity of diabetes and its complications. The engagement of AGEs and RAGE has been implicated in the pathogenesis of diabetic vascular complications, and causes oxidative stress via induction of ROS, which in turn inflammation-related gene expression. An enhanced content of myocardial collagen and its cross-linking with AGEs are proposed as causes for the stiffness of myocardium in diabetes. Chronic degenerative brain disease in diabetes, known as 'diabetic encephalopathy', is a recognized complication that can occur due to longstanding diabetes in patients. It is defined by chronic cognitive disturbance and is thought to relate to regionally occurring pathological tissue changes in the brain. Furthermore, hyperglycemia induced activation of the AGEs/RAGE/NF-B pathway may play an important role in the pathogenesis of the degenerative changes seen in the diabetic hippocampus. AGEs are related to the pathogenesis of peripheral neuropathy, nephropathy and retinopathy in diabetes. The major risk factor for osteoarthritis is aging. The age-related accumulation of AGEs can activate chondrocytes and induce the production of proinflammatory cytokines and matrix metalloproteinases (MMPs). For ameliorating age-related diseases it may be important to inhibit the advanced glycation of agerelated proteins, which occurs as a consequence of inflammation and oxidative stress. In the following section, the present review focuses on the beneficial effects of representative antioxidants, polyphenols of grape and green tea, on the formation and cross-linking of AGEs.
Grape Polyphenols and Others
By suppressing ROS generation, GSPE can inhibit the enhanced expression of vascular cell adhesion molecule-1 (VCAM-1) but not of intercellular adhesion molecule-1 (ICAM-1) in AGEs-exposed endothelial cells [95] . GSPE reduces not only VCAM-1 expression in human umbilical vein endothelial cells but also von Willebrand factor (vWF) contents. GSPE protects the function of endothelial cells through activation of PPAR expression and inhibition of RAGE expression [96] . Treatment with GSPE reduces AGEs formation, levels of RAGE, and mRNA expression of NF-B and TGF-in myocardial tissue of rats with STZ-induced diabetes [97] . In AGE-exposed endothelial cells, GSPE inhibit enhanced expression of RAGE by suppressing ROS generation, thereby limiting the AGE-RAGE interaction. Thus, GSPE have therapeutic potential in the prevention and treatment of vascular complications in diabetic patients [98] . GSPE are effective in treating diabetic nephropathy, a major cause of morbidity and mortality in diabetic patients. GSPS influence nine kidney proteins, which are involved in oxidative stress, glycosylation damage, and amino acids metabolism in diabetic rats [99] . Long term chronic hyperglycemia causes the over-expression of AGEs/RAGE and NF-B p65 in the hippocampus of rats with STZ-induced diabetes. GSPE decreases the expression of RAGE and NF-B p65 at a daily oral dosage of 250 mg/kg [100] . Diabetic peripheral neuropathy is one of the most common chronic complications of diabetes. GSPE increase the motor nerve conductive velocity, mechanical hyperalgesia and SOD in diabetic rats. GSPE reduce the AGEs and tissue malondialdehyde in diabetic rats and decrease the severe segmental demyelination [101] . Diabetic nephropathy is the most common cause of end-stage renal failure. Treatment with GSPE decreases serum AGEs levels, proteinuria, systolic blood pressure and the progression of nephropathy in diabetic rats [102] . Diabetic retinopathy is a leading cause of visual impairment and blindness among the people of occupational age. GSPE suppress the vascular lesions of central regions and decrease capillary enlargements and neovascularization. Eighteen proteins are found either up-regulated or down-regulated in the retina of STZ-induced diabetic rats. Among them, seven proteins are back-regulated to normal levels by GSPE therapy. They are involved in many important biological processes such as the heat shock response, the ubiquitin-proteasome system, cell proliferation, cell growth and glucose metabolism [103] . GSPE decrease aortic pulse wave velocity, blood pressure, and aortic medial thickness, and inhibit the migration of vascular smooth muscle cells in STZ-induced diabetic rats [104] . Arterial remodeling is the change in structural properties of vessel in diabetes mellitus and contributes to the development of vascular complications. Aortic protein profiles in GSPE-treated diabetic rats show that the expression of 15 proteins is found either down-regulated or up-regulated, as compared to 23 proteins in untreated diabetic rats [105] . Formation of pentosidine, a cross-linking AGE in collagens, is associated with the development of vascular complications in diabetes. Monomeric flavonoids (myricetin quercetin > rutin > (+) catechin > kaempferol) are very potent inhibitors of pentosidine formation in collagens [106] .
Green Tea
Treatment of diabetic rats with green tea reduces increased levels of blood glucose, glycated hemoglobin and systolic blood pressure in rats, and decreases enzyme activities of aspartate transaminase, lactate dehydrogenase and creatine kinase [107] . Decreased solubility of tail tendon collagen is due to increased cross-linking of collagen in diabetic rats. Green tea ameliorates the solubility and reduces cross-linking [108] . Treatment with green tea polyphenols prevents intermittent hypoxia (IH)-induced decreases in spatial bias for the hidden platform during the Morris water maze probe trails as well as IH-induced increases in p47phox expression within the hippocampal CA1 region. Green tea polyphenol reduces malondialdehyde levels and improves IH-induced oxidative stress [109] . Treatment with EGCG protects against glyceraldehyde-derived AGE-induced neurotoxicity, which is associated with an increase in intracellular ROS, as well as against decreases in intracellular catalase and SOD activities. EGCG exhibits protective effects against AGEs-induced injury in neuronal cells through its antioxidative properties, as well as by interfering with AGEs-RAGE interaction mediated pathways, suggesting a beneficial role for this tea catechin against neurodegenerative diseases [110] . Treatment of U937 cells with EGCG induces a significant suppression of apoptotic features such as DNA fragmentation, damage to mitochondrial function, and modulation of apoptotic marker proteins upon exposure to high glucose [111] . EGCG furthermore decreases AGE-stimulated gene expression and production of TNF-and MMP-13 in human chondrocytes, and inhibits DNA binding activity of NF-B by suppressing the degradation of its inhibitory protein I B in the cytoplasm [112] . All flavonoids (catechin, EGCG, luteolin, quercetin and rutin) inhibit hyperglycemia-induced expression of proinflammatory genes and proteins, including TNF-, IL-1 , and COX-2. They also prevent oxidative stress in activated monocytes, as demonstrated by inhibitory effects on intracellular ROS and N -(carboxymethyl)lysine formation caused by hypergycemia [113] .
BIOAVAILABILITY
There is no doubt that all of the naturally occurring polyphenols introduced here possess a broad spectrum of pharmacological and medical properties against oxidative stress and inflammation, and constitute potent candidates for treating TNF--related diseases, such as type 2 diabetes, RA, IBD and AGEs. For a better understanding of the efficacy of polyphenols, it is essential to know their bioavailability, which involves factors such as intestinal absorption, metabolic conversion and urinary excretion, in order to evaluate their in vivo activities after intake. Metabolic conversion begins in the intestinal mucosa where the highest activity of uridine-5'-diphosphoglucuronosyltransferase is found. For example, quercetin mainly accumulates in the form of glucuronide and sulfate conjugates, which still have anti-oxidative ability, whereas no intact quercetin is found in the circulation [114] . Administration of quercetin together with a fat-diet containing triacylglycerols with medium-chain fatty acids enhances the bioavailability of the flavanol due to delayed absorption [115] . Co-treatment of TG2576 mice with fish oil and EGCG reduces Alzheimer's disease-like pathology, suggesting that moderate supplementation with EGCG and fish oil could have synergistic effects on the inhibition of cerebral -amyloid deposits [116] . The low bioavailability of quercetin is due to its insolubility in water and would be limited its use as a food additive or dietary supplement for oral administration. Interestingly, quercetin is a dual inhibitor of cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp), and can influence the bioavailability and pharmacokinetics of other drugs and their metabolites. Quercetin might be promising a candidate for not only anti-diabetic drug but also the inhibitor of P-gp and CYP3A. The bioavailibility of pioglitazone, a drug used in diabetes treatment, is improved by administration together with quercetin [117] . Inhibition of Pgp-mediated efflux and CYP3A-catalyzed metabolism in the intestine by quercetin also leads to enhanced oral bioavailability of another compound etoposide [118] . Oral administration of green tea catechins is absorbed from the intestine, and (-)-epicatechin-3-gallate-glucuronide is the metabolic form that remains in the organism for a longer period of time [119] . Co-administration of quercetin and EGCG with biochanin A, a flavonoid with chemopreventive properties, results in increased flavonoid bioavailability, as well as a decrease in clearance, potentially due to increased enterohepatic cycling [120] . Thus, it is to be expected that combinations of polyphenols with other drugs, which easily undergo the first-pass metabolism by multi-drug resistance transporters efflux in the liver and intestines, would heighten their efficacy.
CONCLUSION
The present review summarizes beneficial effects of naturally occurring polyphenols which are obtained from intake of commonly available foods. There is increasing evidence that several potential candidates might be useful for preventive or therapeutic treatment of diseases related to oxidative stress and TNF-induced inflammation. The authors believe that the efficacy of these candidates is demonstrated by further clinical trials in near future.
[45] Ando, C.; Takahashi, N.; Hirai, S.; Nishimura, K.; Lin, S.; Uemura, T.; Goto, T.; Yu, R.; Nakagami, J. 
Introduction
Nitric oxide (NO) 1 is a radical molecule produced by a variety of cells. NO acts as a neurotransmitter, a vasodilator, and as a cytotoxic immune effector (1) (2) (3) (4) (5) (6) . NO is produced by NO synthase (NOS), which occurs as several isoforms. The constitutive isoforms, such as endothelial NOS and neuronal NOS, are regulated by Ca 2 ϩ and calmodulin. We and others have cloned the inducible isoform (iNOS) from murine macrophages (7) (8) (9) . iNOS is present in activated but not resting macrophages, and it always produces NO when synthesized, so its activity is transcriptionally regulated. We and others isolated the promoter region flanking the iNOS gene and showed that it contains response elements capable of binding transcription factors induced by viral infection, such as nuclear factor-B and IFN response factor-1 (10, 11) . The presence of sequences that potentially activate iNOS transcription in response to viral infection suggests that NO plays a role in responding to viruses.
We used a murine model of viral myocarditis to explore the role of NO during viral infection. The B10.A mouse, when treated with LPS at the time of infection with Coxsackie virus B3 (CVB3), develops maximum viremia within 3 d and can die within 7-10 d. With this system we show that macrophages within myocarditic infiltrates express NOS in virally infected mice, and that inhibition of NOS both increases mortality and accelerates the time course of mortality. The viral load is increased in infected mice that are fed NOS inhibitors, suggesting that NO inhibits viral replication in vivo, as has been reported with in vitro studies by others (12) (13) (14) (15) .
Methods
Materials. The iNOS cDNA was previously cloned by our laboratory (7) . The antibody hybridizing to a subpopulation of macrophages expressing MAC-3 was prepared from a hybridoma cell line from American Type Culture Collection (ATCC; Rockville, MD; M3/ 84.6.34) (16) . The antibody hybridizing to cells expressing the common leukocyte antigen (CLA) antibody was prepared from a hybridoma cell line from ATCC (M1/9.3.4.HL.2) (17). The antibody hybridizing to cells expressing the 5E6 natural killer cell antigen was obtained from PharMingen (San Diego, CA; 01621D) (18) .
Production of an anti-iNOS antibody. A rabbit polyclonal antiiNOS peptide antibody was produced using methods previously described (19, 20) . In brief, a peptide corresponding to the COOHterminal 15 amino acids of iNOS was synthesized (AKKGSALEEP-KATRL) and coupled to thyroglobulin. The conjugate was injected with complete Freund's adjuvant into a New Zealand White rabbit; a booster injection was repeated at monthly intervals, and serum was collected 1 wk afterwards (Hazelton Research, Inc., Denver, PA). The antibody was purified from the serum using an affinity column of peptide conjugated to BSA.
Immunohistochemistry and Western blots. Western blot analysis was performed as described previously (19) . In brief, 200 g of macrophage homogenate was fractionated by SDS-PAGE and then transferred to a nylon membrane, blocked and washed, incubated with the anti-iNOS antibody at a dilution of 1:2,500, and developed with a chemiluminescent system (ECL; Amersham Corp., Arlington Heights, IL; according to the manufacturer's instructions). Immunohistochemistry was performed as described previously (19) . In brief, tissue from paraformaldehyde-perfused mice was frozen in O.C.T. medium, and 4-m-thick serial sections were cut. The tissue slices were mounted on slides, blocked with BSA, incubated with rabbit anti-murine iNOS antibody at dilutions of 1:250, washed, incubated with a secondary biotinylated goat anti-rabbit antibody, washed, incubated with a streptavidin-horseradish peroxidase conjugate, and developed with a kit (Vector Laboratories, Inc., Burlingame, CA; according to the manufacturer's instructions). As controls, tissues were processed similarly with the primary antibody omitted. For quantitation of cellular infiltrates, transverse sections of murine left ventricle were examined at the level of the papillary muscles. A minimum of 20 high-powered fields ( ϫ 400) were examined, and the total number of positive-staining cells per field was counted.
NOS catalytic activity assay. NO production was measured by monitoring the conversion of [ Viral culture. CVB3 was maintained in our laboratory (22, 23) . Aliquots of virus (generous gift of Dr. S. Huber, University of Vermont, Burlington, VT) were plated onto HeLa cells, and the virus was collected from the supernatant and cells, centrifuged, and stored at Ϫ 70 Њ C. Viral virulence was measured by intraperitoneal injection into B10.A mice.
Macrophage culture and stimulation. RAW 264.7 macrophages (ATCC) were grown and stimulated as described previously (7). To prepare extracts of stimulated macrophages, 10-cm plates of 10 7 macrophages were stimulated for 8 h with 3 ng/ml LPS ( Escherichia coli 0111:B4; Sigma Chemical Co.) and 10 U/ml recombinant murine IFN-␥ (gift of the American Cancer Society). The macrophages were then scraped from the plates, suspended in 1 ml PBS, and homogenized in a Dounce homogenizer (Kontes Glass Co., Vineland, NJ).
Murine infection. The murine model of CVB3 myocarditis has been extensively studied in our laboratory (22) (23) (24) (25) . In brief, B10.A mice were injected intraperitoneally with a dilution of CVB3 virus standardized to produce death in 50% of the animals by day 7. On day 2, the mice were injected intraperitoneally with 1 g LPS. Some mice were fed NOS inhibitors in their drinking water (26) . Either 10 mM N G -mono-methyl-arginine (NMMA; Calbiochem Corp., La Jolla, CA) or 100 mM N G -arginine methyl ester (NAME; Sigma Chemical Co.) was supplied as drinking water to control or infected mice. (In later experiments, lower doses of methyl-arginine were used as described in figure legends.) The amount of water consumed and the weight of the mice were recorded to ensure that morbidity and mortality did not reflect differences in hydration. For determining viral content of the hearts of infected mice, mice were killed 5 d after infection, a time point previously determined to be associated with peak cardiac viral titers; 1 g of heart was homogenized in 1 ml 2% MEM medium (GIBCO BRL, Gaithersburg, MD); and 20 l was assayed for viral titer. Viral quantity was then determined by titering homogenate on HeLa cells; serial dilutions were made until a reduction from 100 to 50% of cytopathic effect was seen. To measure the induction of NOS by viral infection, B10.A mice were injected intraperitoneally with 1 ml of HeLa cell supernatant containing CVB3. Hearts and spleens were harvested from control and infected mice 7 d after infection.
Statistics. A Student's t test was used to assess differences in viral titers in hearts between groups of mice given different amounts of NMMA (see Table II ). An ANOVA analysis was used to assess differences in individual cell markers between groups of infected animals at different time points (see Table III ). In all tests, P values of 0.05 or less were considered to indicate statistical significance.
Results
Viral infection activates iNOS in the heart. CVB3 elicits myocarditis in humans (27) and mice (22) (23) (24) (25) . We treated B10.A mice with CVB3 and LPS, and 7 d later we assayed the spleen and heart for NOS catalytic activity (Fig. 1) . In infected mice, negligible NOS activity occurs in the spleen, whereas a massive increase in NOS activity is evident in the heart. Of the several forms of NOS, the neuronal and endothelial enzymes are absolutely dependent upon Ca . Treatment with the chelating agent EDTA fails to decrease cardiac NOS activity in tissue from infected animals. Indeed, a modest increase of NOS activity that is consistently evident in several replications occurs with EDTA (data not shown). The mechanism for this increase is not apparent.
We wished to ascertain whether the activated NOS in the hearts was derived from macrophages and to localize the cellular elements producing NOS using immunohistochemistry. Accordingly, we developed antisera in rabbits immunized with a peptide whose sequence occurs in iNOS but not in neuronal or endothelial NOS. Affinity-purified antibodies were used in Western blots of macrophages in culture stimulated with LPS and IFN-␥ for various times (Fig. 2) . A band corresponding in molecular weight to iNOS, ‫ف‬ 135 kD, is first evident at 4 h and becomes progressively more intense at 6 and 24 h. This corresponds to the known time course for induction of new iNOS protein. Immunohistochemistry of the same populations of macrophages reveals negligible staining in unstimulated macrophages, whereas, 8 h after stimulation with LPS and IFN-␥ , intense staining is evident in discrete regions of macrophage cytoplasm (Fig. 3) .
Immunohistochemistry was used to localize cells expressing iNOS in the spleen and heart of virally infected mice (Fig.   Figure 1 . NOS catalytic activity in myocarditis. Hearts and spleens were collected from control and CVB3-infected B10.A mice on day 7 and assayed for iNOS catalytic activity in the presence of EDTA to abolish constitutive NOS activity. n ϭ 3 mice per data pointϮSEM; P Ͻ 0.05 for CVB3 and CVB3 ϩ LPS hearts vs controls. 4). The spleen is comprised of circular germinal centers or white pulp enriched in lymphocytes, surrounded by the red pulp enriched in mononuclear cells. No iNOS staining is evident in the white pulp, whereas ‫ف‬ 1% of the mononuclear cells in the red pulp stains for iNOS (Fig. 4 A ) . In infected mice, the architectural boundaries of white and red pulp are disrupted. Increased iNOS staining is evident, with ‫ف‬ 10% of the mononuclear cells staining positively (Fig. 4 B ) . This corresponds with the iNOS mRNA localization that we reported previously (7) .
In hearts of control mice, negligible iNOS staining is detected (Fig. 4 C ) , whereas prominent staining occurs in infected mice. Two staining patterns are seen in infected mice. Within focal zones of myocyte necrosis, infiltrating macrophages stain intensely for iNOS. In addition, macrophages staining for iNOS are scattered throughout the interstitial spaces between nonnecrotic myocardial fibers (Fig. 4 D ) . Focal zones of necrosis and diffuse interstitial mononuclear cell infiltrates are the classical histologic pattern found in CVB3 myocarditis in the LPS-treated B10.A murine strain (24, 25) .
Since the mice were treated with LPS as well as virus and LPS alone can induce iNOS, we also examined mice treated with the same dose of LPS but no virus. In these animals, we do not observe iNOS staining in the heart (data not shown). We also examined mice treated with virus alone but no LPS. In these animals, iNOS was expressed in cardiac mononuclear cells (data not shown).
Like B10.A mice, A.SW mice develop myocarditis when treated with CVB3, although no boost with LPS is necessary for development of the late phase of myocarditis. In some experiments, we treated A.SW mice with CVB3 in the absence of LPS and examined their hearts 7 d later (data not shown). The pattern and extent of iNOS staining in the heart is essentially the same in these mice as in the B10.A mice.
NOS inhibitors increase mortality and viral titer.
The activation of iNOS in the hearts of virally infected mice could represent an antiviral immune response or a postviral immune response that damages the heart. Discriminating between these alternatives might be feasible by ascertaining whether inhibition of NO formation is therapeutic or worsens the clinical state of the animals. Accordingly, we treated mice with two inhibitors of NOS, NMMA or NAME (Table I) . Feeding NMMA or NAME to control or LPS-treated mice does not produce significant mortality. Viral infection alone produces 40-50% mortality. Virtually all infected animals treated with NAME or NMMA die.
To explore possible mechanisms for the increased mortality produced by NOS inhibitors, we monitored the viral titer in myocardial extracts of mice fed different amounts of NMMA (Table II ). An increase in viral titer is evident with a Ͼ 1,000-fold increase of viral titer at the highest dose of NMMA.
NOS inhibitors increase inflammatory infiltrates in hearts of infected mice. To determine the effect of NOS inhibition upon the kinetics of immune cell infiltration into the heart, mice were harvested at days 3, 5, and 9 after infection with CVB3; sections of their hearts were processed for immunohistochemistry with antibodies against the MAC-3, CLA, and natural killer markers; and the numbers of staining cells were counted per high-power field. Inhibition of NOS is associated with a mild increase in macrophages infiltrating into the heart after 3 d of infection and an increase in natural killer cells after 3 and 5 d of infection, but after 9 d of infection the numbers of cells expressing MAC-3, CLA, and natural killer markers are approximately equal (Table III) . (The large standard deviations in cell counts are due to the focal nature of the disease.)
Discussion
Our study provides several lines of evidence indicating a major role for NO in defending against viral infections, at least in the case of Coxsackie virus myocarditis. Other investigators have reported that infection with various viruses induces expression of iNOS in vitro (12, 13, 15, (28) (29) (30) (31) . MacMicking and associates (13) have observed that transfection of iNOS cDNA into cells in culture decreases viral titer in these cells. Croen (12) observed that induction of iNOS in virally infected macrophages decreases viral titer in these cells.
We provide evidence that this antiviral effect of NO observed in vitro plays a role in an organism's response to viral infection. Thus, we show that viral infection produces a profound augmentation of iNOS in the heart. Evidence that NO protects the animal from damaging effects of early virus-mediated injury comes from our experiments in which NOS inhibitors increase viral titer and mortality.
NO is a prominent vasodilator that also inhibits platelet aggregation. One potential role of NO in inflammatory responses could be relatively nonspecific: namely, to increase vascular perfusion of the infected areas, permitting lymphocytes to infiltrate and produce selective antiviral antibodies. Some studies suggest that NO may reduce inflammatory responses by decreasing neutrophil adherence to endothelium (32) (33) (34) (35) . Our findings favor a direct antiviral role of NO in response to infection. This would fit with the established antibacterial effects of NO (36) (37) (38) (39) (40) (41) .
In this murine myocarditis model, viral infection stimulates infiltrating mononuclear cells to secrete IFN-␥ , IL-1 ␤ , IL-6, and TNF-␣ (24, 25, 42, 43) . In addition, CVB3-induced production of IL-1 ␤ , IL-6, and TNF-␣ has been demonstrated in human monocytes (44) . We (10) and others (11) have shown that the regulatory region of the iNOS gene contains specific recognition sites for transcription factors induced by IL-6, TNF-␣ , and IFN-␥ . By deletion analysis, we have shown regulatory functions for these regions in the induction of iNOS. The release of these cytokines from mononuclear cells probably stimulates the expression of iNOS during viral infection. Immunohistochemistry with the anti-iNOS antibody shows that iNOS is absent in spleens of control mice ( A ) but present in spleens from infected mice ( B ). Control animals do not express iNOS in their heart ( C ), but infected animals express iNOS in their hearts in an infiltrative pattern ( D ). The magnification is 400. Noninfected control mice given LPS alone on day 2 do not express iNOS in their heart on day 7 (data not shown). 
Mice were infected with a fixed dose of Coxsackie virus, and their mortality was observed after 7 d. Some mice were fed 10 mM NMMA or 10 mM NAME in drinking water. Data are reported as dead mice/total mice for each data point. Cytokines can also induce iNOS expression in cardiac myocytes in vitro (45-47), and iNOS can be expressed in cardiac myocytes and microvascular endothelial cells in animal models of inflammation such as cardiac allograft rejection (48-50). However, by immunohistochemistry we did not detect iNOS expression in cardiac cells other than infiltrating mononuclear cells. It is possible that iNOS is expressed in cardiac myocytes at a low level that is not detected by immunohistochemistry but at a level sufficient to synthesize enough NO to block viral replication. Since the number of cardiac myocytes is much greater than the number of infiltrating mononuclear cells, a small amount of iNOS expressed in many cardiac myocytes could generate more NO than a large amount of iNOS in relatively few macrophages.
After induction of iNOS by cytokines, the elaborated NO elicits direct antiviral effects. This response would appear to reflect a rapid but nonspecific type of immune activity, contrasted with the slower but highly site-specific recognition actions of antibodies and T cell receptors.
How does NO inhibit viral replication? Conceivably, NO could exert an antiviral effect through its influences upon the host cell. NO can influence cell metabolism in several ways. It inhibits glyceraldehyde-3-phosphate dehydrogenase, thus diminishing glycolysis (51-55), cis -aconitase (56, 57), and mitochondrial respiratory enzymes (58), and perhaps it can affect the Krebs cycle. As NO has been demonstrated to damage DNA (59-61), it can probably also damage viral RNA. The known ability of NO to inhibit ribonucleotide reductase (62, 63) may also influence viral replication. NO can also affect the viral life cycle by influencing intracellular signaling pathways regulated by oxidation of sulfhydryl groups (29) . NO might bind to metal ions in viral proteins that are required for replication. Thus, a nitroso compound was shown to reduce HIV infectivity by ejecting zinc from a transcription factor that contains a zinc finger motif (64). Whereas the CVB3 genome does not contain zinc finger motifs, NO could conceivably influence metal ions of other transcription factors. NO can inhibit cell proliferation, but Coxsackie is a picornavirus whose replication involves a viral RNA-dependent RNA polymerase and thus is not absolutely dependent upon host cell replication.
Inhibition of NOS is associated with a temporary increase in immune cell infiltration into the hearts of infected mice (Table III). Although macrophages are more prominent in hearts of treated mice after 3 d of infection, and although natural killer cells are more prominent in the hearts of treated mice after 3 and 5 d of infection, the numbers of infiltrating cells are the same after 9 d of infection in the hearts of treated and untreated mice. Perhaps more macrophages and natural killer cells migrate into the heart because NOS inhibition permits viral replication to increase, inducing higher levels of local cytokine production, which in turn stimulates additional mac- 
, and that the Aboriginal ancestors split 62,000 to 75,000 years B.P. from the gene pool that all contemporary nonAfrican populations appear to descend from. Rather than supporting a single early human expansion into eastern Asia, our findings support the alternative model of Aboriginal Australians descending from an early Asian expansion wave some 62,000 to 75,000 years B.P. The data also fit this model's prediction of substantial admixture and replacement of populations from the first wave by the second expansion wave, with a few populations such as Aboriginal Australians, and possibly PNG Highlands and Aeta, being remnants of the early dispersal (Fig. 2) . This is compatible with mtDNA data showing that although all haplogroups observed in Australia are unique to this region, they derive from the same few founder haplogroups that are shared by all nonAfrican populations (4). Finally, our data are in agreement with contemporary Aboriginal Australians being the direct descendants from the first humans to be found in Australia, dating tõ 50,000 years B.P. (7, 8) . This means that Aboriginal Australians likely have one of the oldest continuous population histories outside subSaharan Africa today. Neural circuits regulate cytokine production to prevent potentially damaging inflammation. A prototypical vagus nerve circuit, the inflammatory reflex, inhibits tumor necrosis factor-a production in spleen by a mechanism requiring acetylcholine signaling through the a7 nicotinic acetylcholine receptor expressed on cytokine-producing macrophages. Nerve fibers in spleen lack the enzymatic machinery necessary for acetylcholine production; therefore, how does this neural circuit terminate in cholinergic signaling? We identified an acetylcholine-producing, memory phenotype T cell population in mice that is integral to the inflammatory reflex. These acetylcholine-producing T cells are required for inhibition of cytokine production by vagus nerve stimulation. Thus, action potentials originating in the vagus nerve regulate T cells, which in turn produce the neurotransmitter, acetylcholine, required to control innate immune responses.
R. E. Green et al., Science
N eural circuits regulate organ function in order to maintain optimal physiological stability, providing homeostasis to the body's internal environment. The vagus nerve, named by the Latin word for "wandering," is a paired structure that arises in the brain stem and travels to visceral organs, where it regulates physiological responses to environmental changes, injury, and infection. In the immune system, electrical stimulation of the vagus nerve inhibits cytokine release; attenuates tissue injury; and ameliorates inflammation-mediated injury in endotoxemia, sepsis, and other cytokine-dependent models of inflammatory disease (1) (2) (3) (4) . This neural circuit, termed the inflammatory reflex, requires action potentials arising in the vagus nerve, and acetylcholine interacting with the a7 subunit of the nicotinic acetylcholine receptor (nAChR) expressed on cytokineproducing macrophages in spleen (5) . Selective cholinergic agonists significantly inhibit cytokine production in spleen and improve outcome in experimental models of inflammatory disease (6-12).
Vagus nerve fibers terminate in the celiac ganglion, the location of neural cell bodies that project axons in the splenic nerve to innervate the spleen (13, 14) . Electrical stimulation of either the vagus nerve above the celiac ganglion or the splenic nerve itself significantly inhibits tumor necrosis factor-a (TNF-a) production by red pulp and marginal zone macrophages, the principal cell source of TNF-a released into the circulation during endotoxemia (15) (16) (17) . Paradoxically, nerve fibers in spleen, originating in the celiac ganglion, are adrenergic, not cholinergic, and utilize norepinephrine as the primary neurotransmitter (18) . Thus, although the spleen has been shown to contain acetylcholine (19, 20) , the cellular source of this terminal neurotransmitter in the inflammatory reflex is unknown. Because lymphocytes can synthesize and release acetylcholine (21, 22) , we reasoned that they might be the source of acetylcholine that relays functional information transmitted by action potentials originating in the vagus nerve to the spleen.
To determine whether vagus nerve stimulation induces increased acetylcholine release in the spleen, we measured acetylcholine in perfusate samples collected by microdialysis. Acetylcholine levels were elevated within minutes after electrical vagus nerve stimulation and reached peak levels within 20 min (Fig. 1A) . This indicates that action potentials originating in the vagus nerve can enhance acetylcholine release in the spleen. Previous work indicated that adrenergic nerve endings in the spleen terminate in the T cell region of the white pulp and that splenic nerve stimulation enhances norepinephrine release from spleen (23, 24) . To determine the effect of norepinephrine on acetylcholine release, we incubated spleen lymphocytes in the presence of norepinephrine. Norepinephrine significantly stimulated acetylcholine release by spleen lymphocytes (Fig.  1B) , which suggested that functional stimulation of adrenergic splenic neurons can stimulate spleen lymphocyte acetylcholine release.
Next, to evaluate the role of T cells in mediating the inflammatory reflex, we studied the effect of vagus nerve stimulation in nude mice, which are devoid of functional T cells. As expected, vagus nerve stimulation in control BALB/c mice significantly suppressed serum TNF-a production during endotoxemia (Fig. 1C) . Vagus nerve stimulation failed to attenuate serum TNF-a in nude mice, which indicated that T cell deficiency impairs the inflammatory reflex (Fig. 1D) . To identify acetylcholine-producing T cells required for the integrity of the inflammatory reflex, we used ChAT(BAC)-EGFP mice, which express enhanced green fluorescent protein (EGFP) under the control of transcriptional regulatory elements for ChAT, the enzyme that catalyzes the biosynthesis of acetylcholine (25) . Flow cytometry revealed that ChAT-EGFP + cells were 2.6 T 0.4% of total spleen CD3 + T cells ( Fig. 2A) , which indicated that only a relatively small subset of total spleen T cells express ChAT. ChAT-EGFP was expressed in 4.4 T 0.7% of CD4 + cells, but in only a negligible number (0.2 T 0.1%) of CD8 + T cells (Fig. 2B) (Fig. 2, E and F) . To functionally characterize these acetylcholine-producing T cells, spleen CD4 + CD44 high CD62L low ChAT-EGFP + cells were stimulated with plate-bound CD3-specific antibody. Levels of interleukin-17A (IL-17A), IL-10, and the T helper 1 cytokine interferon-g (IFN-g) were significantly elevated in supernatants 48 hours after stimulation ( fig.  S1 ), whereas the T helper 2 cytokines IL-4 and IL-6 were not significantly elevated ( fig. S1 ). This suggested that ChAT expression is not restricted to a discrete functional T cell subset and raised the possibility that T cell acetylcholine-synthesizing capacity might be linked to T cell activation status. To examine this, ChAT-EGFP expression was analyzed on CD4 + CD44 high CD62L low ChAT-EGFP -T cells after stimulation with CD3-specific antibody. Flow cytometry analysis revealed a significant increase in ChAT-EGFP expression within 48 hours after T cell stimulation ( fig. S2 ), which suggested that T cell activation enhances expression of ChAT and acetylcholine release.
The spatial relation between ChAT-EGFP + T cells and splenic nerve fibers was explored by immunofluorescence analysis of spleen sections to reveal that ChAT-EGFP expression in T lymphocytes localized primarily in the white pulp (Fig. 3, A and B) . ChAT-EGFP + cells in the white pulp were adjacent to splenic nerve fibers expressing tyrosine hydroxylase, the rate-limiting enzyme in catecholamine synthesis (Fig. 3C) . As expected, splenic nerve fibers failed to express ChAT-EGFP, in agreement with earlier results, which indicated that splenic nerves are adrenergic and do not produce acetylcholine (15, 18) .
Synaptophysin, a glycoprotein expressed at neural synapses, was localized adjacent to ChAT-EGFP + cells in white pulp parenchyma (Fig. 3D ). Together with previous results indicating that splenic nerve endings form synapse-like structures on T lymphocytes (23) , the termination of these synaptophysin-positive nerve fibers on ChAT-EGFP + T cells provides an anatomical basis for splenic nerve fibers interacting with acetylcholineproducing T cells. Extensive prior work has established that splenic nerve signals modulate T cell responses by signal transduction through b-adrenergic receptors (26) (27) (28) . Analysis of mRNA levels of adrenergic receptors b1, b2, and b3 in CD4 + CD44 high CD62L low ChAT-EGFP + spleen b1 and b2, but not b3 (fig. S3 ). This agrees with previous work that b-adrenergic receptors on T cells underlie the mechanism of adrenergic splenic nerve signaling (26) (27) (28) .
In S4, A and B) . We also observed significant accumulation of ChAT-EGFP + cells in the vicinity of synaptophysin-positive nerve fibers in white pulp ( fig. S4C ). The localization of ChAT-EGFP + T cells in the white pulp of nude mice after adoptive transfer was indistinguishable from that of ChAT-EGFP + T cells observed in transgenic ChAT(BAC)-EGFP mice (Fig. 2) . Together, these results indicate that acetylcholine-producing T cells populate the spleen after adoptive transfer and localize to the region of splenic neurons under functional control of action potentials originating in the vagus nerve.
It remained theoretically possible that some other unanticipated effect of these cells not related to acetylcholine restored the inflammatory reflex. Accordingly, we next utilized small interfering RNA (siRNA) to deplete (knockdown) ChAT in spleen CD4 + T cells ( fig. S5 ). Scrambled or ChAT siRNA-transfected CD4 + T cells were adoptively transferred into nude mice. Vagus nerve stimulation attenuated serum TNF-a levels in mice that received CD4 + T cells transfected with control siRNA (Fig. 4C) , but failed to attenuate TNF-a in nude mice that received CD4 + T cells transfected with ChAT siRNA (Fig. 4D) . Vagus nerve stimulation also significantly reduced serum IL-6 and IL-10 levels in nude mice that received CD4 + T cells transfected with control siRNA, but not in nude mice that received ChAT siRNA-treated T cells ( fig. S6 ). Together, these data indicate that T cells with an intrinsic capacity to synthesize acetylcholine are required for the integrity of the inflammatory reflex.
It had been previously established that the inflammatory reflex requires an intact splenic nerve (15) and a7 nAChR expression in effector cytokine-producing cells in spleen (16) . These results were previously difficult to rectify with observations that splenic nerves are adrenergic and do not produce the neurotransmitter, acetylcholine, required to interact with a7 nAChR. As early as 1965, investigators had observed that electrical stimulation of the splenic nerve induced acetylcholine release in spleen, but the cell source of this acetylcholine had been contested (29) (30) (31) (32) . The present findings show that vagus nerve stimulation also increases acetylcholine release from spleen and that spleen lymphocytes release acetylcholine in response to norepinephrine. It is likely that the regulatory effect of acetylcholine-synthesizing T cells described here is not restricted to the spleen, because CD4 + CD44 high CD62L low ChAT-EGFP + T cells are also present in lymph nodes and Peyer's patches ( fig. S7 ), which are innervated by adrenergic neurons (33) . Further, polyclonal activation of T cells also up-regulates ChAT-EGFP expression ( fig. S2 ) (34) and augments acetylcholine production and release (35) , which together make plausible the possibility that T cell activation status modulates the activity of the inflammatory reflex.
A major finding of this study is the surprising functional role for acetylcholine-producing memory T cells as integral components of a neural information system that controls innate immune responses. It should be possible to target these cells as therapeutic modalities for inflammatory and autoimmune diseases. Systemic immunosuppression has been associated with stroke for many years, but the underlying mechanisms are poorly understood. In this study, we demonstrated that stroke induced profound behavioral changes in hepatic invariant NKT (iNKT) cells in mice. Unexpectedly, these effects were mediated by a noradrenergic neurotransmitter rather than a CD1d ligand or other well-characterized danger signals. Blockade of this innervation was protective in wild-type mice after stroke but had no effect in mice deficient in iNKT cells. Selective immunomodulation of iNKT cells with a specific activator (a-galactosylceramide) promoted proinflammatory cytokine production and prevented infections after stroke. Our results therefore identify a molecular mechanism that leads to immunosuppression after stroke and suggest an attractive potential therapeutic alternative to antibiotics, namely, immunomodulation of iNKT cells to prevent stroke-associated infections.
A major cause of death resulting from stroke is infection (1, 2) . Immunosuppression, perhaps due to a systemic shift from T helper cell (T H ) 1-type to T H 2-type cytokine production, has been proposed as a compensatory response to protect the post-ischemic www.sciencemag.org SCIENCE VOL 334 7 OCTOBER 2011
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The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation
Introduction
Survival is impossible without the precise regulation of the immune system. The production of proinflammatory cytokines is a critical physiological process to orchestrate immune and metabolic responses during development, tissue regeneration, healing, trauma or infection, and to protect our bodies against hemorrhage, ischemia, cancer and sepsis. A controlled production of proinflammatory cytokines, such as interleukins (ILs), tumor necrosis factoralpha (TNF-a) and high-mobility group box (HMGB)-1, triggers beneficial inflammatory responses that promote local coagulation to confine infection and tissue damage (Ulloa and Tracey, 2005) . However, the unrestricted production of these cytokines is more dangerous than the original injury and it is one of the principal causes of human morbidity and mortality. One of the most dramatic examples of this process is 'severe sepsis', the leading cause of death in intensive care units and one of the principal causes of death in developed societies (Martin et al., 2003 (Figure 1 ). Beyond its physiological implications, this mechanism provides major advantage for the design of novel pharmacological anti-inflammatory strategies. This article reviews the current understanding of the regulation of innate immune responses by the parasympathetic nervous system and its pharmacological translation for the treatment of infectious and inflammatory disorders.
A neuronal strategy for inflammation
Vagal modulation of immune responses may have particular implications in the densely innervated gastrointestinal tract. The intestinal lumen contains massive numbers of commensal gut microbes (estimated to amount 10 11 to 10 12 per gram stool in the colon (Sansonetti, 2006) ) and the immune system must display a regulated response to either beneficial or pathogenic microbes (Backhed et al., 2005) . The parasympathetic nervous system, which classically assigned The anti-inflammatory effects of efferent vagus nerve activity on the GI-tract are in agreement with previous studies indicating that surgical vagotomy increases the susceptibility of rodents to systemic inflammation in septic and hemorrhagic shock . Hence, the vagus nerve can function as a physiological anti-inflammatory system and the clinical potential of this mechanism is not necessarily limited to the gastrointestinal tract, but extends to several clinical scenarios including injury, trauma, hemorrhage and severe sepsis. Electrical stimulation of the vagus nerve inhibits systemic levels of proinflammatory mediators such as TNF, IL6, IL1b and HMGB-1 in experimental models of endotoxemia, hemorrhagic shock and polymicrobial sepsis. Recent studies indicated that the spleen is crucial in mediating these systemic effects, as electrical stimulation of the vagus nerve fails to attenuate serum TNF levels in splenectomized animals . Moreover, selective lesioning of the common celiac nerve abolishes TNF suppression by vagus nerve stimulation . This connection between the common celiac nerve and the spleen reveals that the parasympathetic nervous system may modulate systemic inflammation by regulating immune cells in the spleen.
In addition to its physiological implications, recent studies reveal a previously unrecognized role of the vagal nerve in mediating the anti-inflammatory potential of specific pharmacological agents. The vagal nerve seems to contribute to the anti-inflammatory potential of a wide diversity of compounds such as many nonsteroidal anti-inflammatory drugs, semapimod (CNI-1493) and melanocortin peptides. Similar to CCK, leptin, melanocortin peptides and some nonsteroidal anti-inflammatory drugs appear to control the production of pro-inflammatory cytokines through an antiinflammatory mechanism mediated by the vagus nerve (Ulloa, 2005) . Among others, semapimod and adrenocorticotropic hormone activate the efferent vagus nerve and limit circulating serum TNF levels during endotoxemia through a mechanism that requires an intact vagus nerve as surgical vagotomy abrogates their anti-inflammatory potential (Bernik et al., 2002) .
Acetylcholine and inflammation
At molecular level, most of the studies about the antiinflammatory potential of the vagus nerve have been based on the effects of acetylcholine, the principal neurotransmitter of the parasympathetic nervous system. Acetylcholine receptors are prominently expressed in immune cells, and those cells derived from bone marrow (lymphoid and myeloid cells). The functional implications have become clear after the finding that acetylcholine controls the production of proinflammatory cytokines from macrophages . Since acetylcholine signals through either muscarinic (G-protein-coupled receptors) or nicotinic (ligand-gated ion channels) receptors (Miyazawa et al., 2003) , selective cholinergic agonists and antagonists were used to identify the receptors involved in the control of macrophage activation. Muscarine slightly inhibited macrophage activation at supraphysiological levels, but nicotine was more efficient than acetylcholine at inhibiting the production of pro-inflammatory cytokines from macrophages . These effects were specific for proinflammatory cytokines and neither acetylcholine nor nicotine inhibited the production of anti-inflammatory cytokines such as transforming growth factor b (TGF-b) or IL-10. Hence, the anti-inflammatory effects of acetylcholine on macrophages seem to be mediated through nicotinic receptors, and nicotine is a more selective pharmacological agonist to control the production of pro-inflammatory cytokines. Transcripts for nicotinic acetylcholine receptors (nAChR) subunit a7, b2, as well as a4 have been detected in multiple inflammatory cell types, including macrophages derived from various tissues (Borovikova et 
Structural and functional aspects of a7 nicotinic acetylcholine receptors (a7 nAChR)
In general, neuronal nAChRs are pentameric complexes of a-and b-subunits that form a ligand-gated ion channel. The large number of different subunits (nine a-and four b-subunits) provides a large variation in possible nAChRs with different physiological function and ligand affinity (Lukas et al., 1999; Drisdel and Green, 2000; Lloyd and Williams, 2000) . The a7 nAChR is a well-characterized member of the neurotransmitter-gated ion channel superfamily (Lukas et al., 1999) . Expression of the a7-subunit gene in several cell types has revealed that assembly of the protein to functional nAChR is complex (Figure 2 ). In neurons, a7 proteins assemble as a homopentamer composed of five individual a7-subunits (Rangwala et al., 1997; Drisdel and Green, 2000), although a7-subunits seem to form functional heteropentamers with b2-subunits if overexpressed in Xenopus leavis oocytes or human epithelial kidney cells tsA201 (Khiroug et al., 2002) . However, assembly of a7-subunits to a functional homopentameric receptor requires assembly protein Ric-3 (Williams et al., 2005) and/or post-translational processing of a7-subunit (Rakhilin et al., 1999) .
The a7-subunit gene includes 10 exons, with 4 transmembrane domains encoded by exons 7-10, 3 putative glycosylation and ligand-binding sites located extracellularly in exons 2-6 (Boyd, 1997; Colquhoun and Patrick, 1997; Lloyd and Williams, 2000) . The a7-subunit is approximately 56 kDa and is composed of 502 aa, including a 22 aa N-terminal signal peptide followed by an extracellular 200-aa ligand-binding domain (Galzi et al., 1991; Bertrand et al., 1993) . The snake toxin a-bungarotoxin is a selective antagonist with high affinity for the a7 nAChR, functionally differentiating this receptor subtype from other neuronal nAChRs ( Figure 2 The a7 nicotinic acetylcholine receptor (a7 nAChR) structure. (a) The Chrna7 is located at the 15q14 chromosomal region. The gene comprises ten exons encompassing 138.5 kb that codifies for the a7 nAChR protein with an estimated MW 50 kDa. Six mRNA splice variants have been described in addition to the wild type a7-gene, though it is uncertain whether any of these transcripts are processed to functional protein. The gen Chrfam7a represents a partial duplication of the human Chrna7 exons 5 to 10. This partial duplicated gene is combined with four novel exons (A to D) to comprise a new gene named 'Cholinergic Receptor FAMily with sequence similarity 7A' (Chrfam7a) or 'hybrid a7'. To date, there is evidence that this gene is transcribed and processed to form a functional receptor. (b) The a7 nAChR has an N-terminal signal peptide and ligand-binding domain, four transmembrane domains (TM1-4), and a regulatory intracellular domain located between TM3 and TM4. (c) Nicotinic acetylcholine receptors (nAChRs) are a family of ligand-gated ion channels created by a diversity of subunits that form homo-or heteropentameric receptors with distinct pharmacological properties. Nicotinic receptors can functionally be differentiated into two principal classes that differ in their affinity for nicotine and a-bungarotoxin. Receptors that bind nicotine with high affinity, contain a2-a6 as ligand-binding subunits, and require b-subunits for proper activation. A second class of receptors (a7-a10) binds nicotine with low affinity; has high affinity for a-bungarotoxin, and functions as homomeric or heteromeric ion channels in vitro. The a7 nAChR forms homo-pentameric ion channel receptors and they appears to be the only a-bungarotoxin receptor identified in macrophages and mammalian brain, as a8-subunits appear to be expressed only in chick, and a9,10-subunits expression is limited to mechanosensory cochlear hair cells and the pituitary.
ligand binding at subunit junctions responsible for changes in the state of the receptor. The transmembrane domains are composed of four a-helices that cross the lipid bilayer and form the ion channel (Boyd, 1997) . Folding and interaction of the extracellular ACh-binding protein loops determine pore opening in response to ACh binding (Bouzat et al., 2004) . Although nicotinic receptors are originally described as sodium channels, the a7 homopentamer is highly permeable for Ca 2 þ as well (Berg and Conroy, 2002) . Phosphorylation of a7 nAChR upon nicotine binding decreases AChevoked currents (Charpantier et al., 2005) . In neuronal cells, the activation of a7 nAChR itself is negatively regulated by phosphorylation at Tyr-386 and Tyr-442 by Src-family kinases that interact directly with its cytoplasmic loop (Charpantier et al., 2005) . Mutant a7 nAChRs lacking cytoplasmic loop tyrosine residues because of alanine replacement of Tyr-386 and Tyr-442 were more active than wild-type receptors and insensitive to kinase or phosphatase inhibition (Charpantier et al., 2005) . The human a7-nAChR gene has been mapped to chromosome 15q14. Six mRNA splice variants of the a7 gene have been described in human brain as well as leukocytes (Gault et , 2004) . Interestingly, the human a7-nAChR has been described to be partially duplicated on this chromosome. Exons 5-10 of the gene have been duplicated in a 'tail-to-head' orientation and this partially duplicated gene is combined with four novel exons (A to D) to comprise a new gene, the 'hybrid a7' or the 'cholinergic receptor family with sequence similarity 7A' (CHRFAM7A) (Gault et al., 1998) . Although it is reported that this gene is transcribed as a 45 kDa protein (that is, in human leukocytes) (Villiger et al., 2002) , it remains unclear whether this hybrid transcript is appropriately translated and processed to form a functional receptor. In cells expressing this hybrid receptor rather than the a7 containing all exons, no binding of a-bungarotoxin and no nicotine-induced electrical current could be demonstrated (Villiger et al., 2002) , possibly explained by the fact that the hybrid gene is mutated in the binding site for nicotine and a-bungarotoxin. Future studies are needed to determine whether the various gene products of a7 comprise nonfunctional splice variants, or have a role in the cellular responses to ACh.
Functional aspects of a7 ACh receptor activation on immune cells
The bone marrow is innervated by parasympathic cholinergic nerve fibers and several types of bone marrow-progenitorand other myeloid and lymphoid cells (B-cells, microglia, monocytes and dendritic cells (DC)) are functionally responsive to nicotine and express the a7 receptor.
T lymphocytes
Thymic epithelium as well as T cells in the thymus express nAChR as do mature lymphocytes (Fujii et al., 1999) . The . It should be noted however that in addition to a7, heteromeric a4/b2 nAChRs are found on B lymphocytes (Skok et al., 2005) , and deficiency of those subunits affects both the pre-immune status of mice and their immune response. Both of these nicotinic receptors seem to affect signaling and expression of co-stimulatory CD40 on B-cells. The functional contribution of a7 or a4/b2 nAChR subtypes to the biological effects of nicotine or ACh is unclear. Studies indicate that both a4/b2 and a7 nAChRs may be involved in the maturation of pre/pro B cell in the bone marrow to develop into circulating B cells. Using bonemarrow reconstituted chimeras of genetically modified mice strains that lack either of the two receptors in their bone marrow progenitor cells, it was shown that both a7 or b2 nAChR stimulate B-cells development from the pre-B-cell stage (Skok et al., 2006) . The lack of either of the 2 nAChRs, but in particular of a4/b2 nAChR, decreased peripheral B-cell number, whereas on the other hand, nicotine treatment increased B lymphocyte numbers in the bone marrow.
Dendritic cells
While macrophages initiate many inflammatory and innate immune functions, DCs are the principal antigen-presenting cells (APCs) and are critical cells for initiation of cellmediated immunity against infection. A series of in vitro studies report that DCs express the a7 nAChR and that The reason for these opposite effects may involve DC maturation status at the time of assay, rendering the in vivo implications of cholinergic modulation of DCs on inflammatory disease hard to appreciate. Clearly, the expression of a7 nAChR in DCs is suggestive of vagal (cholinergic) regulation of their activity, but further, in vivo, studies are required to determine a role of the vagal nerve in modulating their function in animal models of inflammation.
Monocytes, macrophages and neutrophils
Macrophages are critical effector cells for early recognition and destruction of organisms invading through most surfaces including the gut, skin and lung. Studies reporting that nicotine and/or cigarette smoke alter macrophage functions, such as pinocytosis (Schwartz et al., 1972; Schwartz, 1976) , endocytosis and intracellular degradation of phagocytosed protein (Thyberg et al., 1983 ) and killing of microbes date back some 25-40 years (Green and Carolin, 1967) . However, most of these effects were attributed to accumulation of nicotine in the lysosomes leading to an impaired digestive capacity (Thyberg et al., 1983) . In monocytes and macrophages of various species, nicotine causes alteration of macrophage functions such as microbial killing (Green and Carolin, 1967 (Matsunaga et al., 2001) . Further, the production of the inflammatory cytokines IL-6, TNF and IL-12 was downregulated by nicotine in these cells. A potential outcome of this effect may be that, on the one hand, the inflammatory responses become less, but on the other the anti-inflammatory properties of nicotine actually enhance the survival of invading microbes or viruses and induce significantly higher titers of virus following infection (Sopori, 2002) . Of note, in this respect, may be that certain infections, such as pneumonia caused by Streptococcus pneumoniae, are more frequent in smokers (Nuorti et al., 2000) . Hence, these studies suggest that an acute treatment with nicotinic agonists may provide a pharmacological strategy to restrain inflammation, but chronic exposure to nicotine or nicotinic agonists may provide a sustained antiinflammatory potential that favors some lung infections as observed in tobacco smokers and their susceptibility to chronic obstructive pulmonary disease (Barnes, 2003) . In addition to macrophages, nicotine alters various neutrophil functions such as superoxide anion production (Sorensen et al., 2004) , chemotaxis (Totti III et al., 1984) , integrin expression (Speer et al., 2002) and chemokine production (Iho et al., 2003) , and suppresses apoptosis (Aoshiba et al., 1996) . However, although neutrophils express nicotinic receptors (Davies et al., 1982) , it is yet unclear whether these effects are mediated by the a7 nAChR.
Myeloid cells; microglia
Microglia cells represent the largest class of phagocytes within the central nervous system (CNS). In parallel to activation of phagocytes in non-neuronal tissues, the outcome of activation of microglia can be either neuroprotective or neurotoxic. It is generally recognized that healthy neurons and astrocytes in the microenvironment can regulate the magnitude of microglia-mediated innate immune responses via activation of a7 nAChRs, among other neurotransmitter receptors such as purinergic P2X7 receptors (Suzuki et al., 2006) In normal healthy brain, microglia show a typical resting phenotype when compared to other tissue macrophages, but they rapidly react in response to a number of acute and chronic insults. Activated microglia can be of crucial importance in CNS pathology via liberation of free radicals as well as cytokines and toxic factors (Streit, 2002) . Alternatively, microglia can exert neuroprotective functions by secreting growth factors or diffusible anti-inflammatory mediators, which help to resolve inflammation and restore tissue homeostasis (Streit, 2002) . Cultured microglia express a7 nAChR protein and mRNA, nicotine and ACh inhibit production of TNF in LPS-stimulated mouse microglial cultures (Shytle et al., 2004) . This inhibition in TNF production is associated with a reduction in phosphorylation of p44/42 and p38 MAPK (Shytle et al., 2004; Suzuki et al., 2006) . Nicotine also acts as an anti-inflammatory agent on microglia by increasing the expression of COX-2 and the synthesis of PGE2, known to downregulate microglial activation and expression of pro-inflammatory genes, including TNF (Zhang and Rivest, 2001; Suzuki et al., 2006) . However, nicotine has no effect on the release of NO, IL-1b and IL-10. The effect of nicotine on the LPS-induced TNF production and PGE2 release is counteracted by the specific antagonist of the a7-subunit, a-bungarotoxin, demonstrating the requirement of a7 nAChR.
Nicotine may be protective against the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, in which a local inflammatory response is sustained by microglial cells (Streit, 2002; Hellstrom-Lindahl et al., 2004; Wang et al., 2000a, b) . The potential of the a7 nAChR in mediating CNS inflammation has gained clinical interest since the implication of a7 nAChR in b-amyloid (Abeta (1-42)) neurotoxicity, a critical factor in the pathology of Alzheimer's disease. One of the major features of it is the reduction of nAChRs in disease-relevant brain regions such as the cerebral cortex and hippocampus. This loss is explained by the loss of cholinergic cells, which contributes to the cognitive dysfunction. The most vulnerable neurons appear to be those that abundantly express the a7 nAChR. In vivo studies clearly indicate that a7 nAChRs play a critical role in protection from cholinergic lesions and enhancing cognitive function (Hellstrom-Lindahl, 2000) . Many data point towards binding of Abeta to the a7 nAChR as the triggering factor in neuronal cell death and Alzheimer's pathology. The high-affinity binding of Abeta to the a7 nAChR on neuronal cell surfaces leads to internalization of the nAChR complex and its accumulation within the lysosomal compartment (Wang et al., 2000a, b) . Because this a7 nAChR-Abeta (1-42) interaction also leads to the inhibition of ACh release and calcium flux, and even cell death in vitro, it is speculated that this interaction may be one of the key events in the pathogenesis of Alzheimer's disease.
Evidence is provided that a7 nicotinic agonists are neuroprotective against Abeta (1-42) toxicity in various culture systems. This effect appears to be mediated by a7 subtype nAChRs, since the protection is blocked by a-bungarotoxin and is mimicked by a7 selective agonists (Shaw et al., 2002 (Shaw et al., , 2003 Marrero et al., 2004) . In the neuronal cell line PC12, nicotine interaction with the a7 nAChR inhibits binding of Abeta to the same receptor, and prevents the Abeta (1-42)-induction of caspase 3 and apoptosis. The latter seems to be the result of nicotinic activation of tyrosine kinase Janus kinase 2 (Jak2) and activation of phosphatidylinositol 3-kinase and Akt-signaling pathways rather than blockade of Abeta binding to the a7 nAChR (Shaw et al., 2002) . In turn, nicotine-induced Jak2 kinase activity is negatively mediated by activity of the cytoplasmic phosphatase Src-homology phosphatase-1 (Shaw et al., 2003) . Notably, phosphorylation of the a7 nAChR (Charpantier et al., 2005) and activation of Jak2 by nicotinic binding to a7 nAChR has also been demonstrated in non-neuronal cell types such has macrophages 
Pharmacological implications for nicotinic agonists
Nicotine is an alkaloid found in the nightshade family of plants (Solanaceae), predominantly in tobacco, and in lower quantities in tomato, potato, eggplant and green pepper. Recent studies indicate that nicotine inhibits the production of pro-inflammatory cytokines in macrophages by preventing the activation of the NF-kB through a mechanism dependent on the a7 nAChR. In peritoneal macrophages, the a7 nAChR can recruit the tyrosine kinase Jak2 and promotes STAT3 phosphorylation and subsequent activation. The Jak2-STAT3 pathway can contribute to the anti-inflammatory potential of the a7 nAChR by inducing the expression of anti-inflammatory proteins such as SOCS3.
Nicotine is named after the tobacco plant Nicotiana tabacum, which in turn was named after Jean Nicot, a French ambassador in Portugal. In 1560, after treating the Queen of France, Catherine de Medici, for her migraine headaches, Nicot wrote of tobacco's therapeutic properties in cancer, healing and inflammation. Currently, the primary therapeutic use of nicotine is in treating smoking-induced addiction. The original characterization of nAChRs in neurons prompted the study of nicotine and its metabolites in a wide diversity of neurological disorders (depression, Tourette's syndrome, autosomal dominant frontal lobe epilepsy, attention-deficit hyperactivity disorder, Parkinson's disease, and Alzheimer's disease). Likewise, the recent characterization of nicotinic receptors in immune cells evoked the study of nicotinic agonists and their pharmacological and clinical implications in infectious and inflammatory disorders.
To date, chronic obstructive pulmonary disease (COPD) is probably one of the most significant clinical implications of nicotine in infectious and inflammatory disorders. COPD is one of the commonest causes of morbidity and mortality in the world and smoking cessation is the only strategy that reduces this decline in lung function (Barnes, 2003) . The mainstay of treatment of COPD is bronchodilators for symptom relief and inhaled anticholinergics and b2-agonists are useful by reducing hyperinflation of the lungs. By contrast, inhaled corticosteroids are poorly effective and do not reduce disease profession (Barnes, 2003) .These effects are in agreement with those studies suggesting that chronic exposure to nicotine provides a sustained anti-inflammatory potential that favors lung infections, such as pneumonia caused by S. pneumoniae, are more frequent in smokers (Nuorti et al., 2000) . Likewise, one of the most compelling evidence supporting the therapeutic anti-inflammatory potential of nicotine is epidemiological studies of smokers in ulcerative colitis, a characteristic inflammatory bowel disorder that often results in colon cancer. Ulcerative colitis is a continuous idiopathic inflammation of the colonic or rectal mucosa that is normally associated with loss of tolerance to indigenous enteric flora, abnormal humoral and cell-mediated intestinal immunity, and/or generalized enhanced reactivity against intestinal bacterial antigens. About 90% of the victims of ulcerative colitis are nonsmokers. Among sectors, the rates of ulcerative colitis are five times higher among nonsmoking Mormons than in the general population. Patients with a history of smoking acquire their disease after they have stopped smoking (Pullan et . In ex-smokers, onset is nearly always after quitting smoking. Smoking appears to have a protective effect against the development of this disease and also reduces its severity. This is important because the earlier it occurs, and the more extensive it is, the greater is the risk of future colorectal cancer. Colorectal cancer risk in ulcerative colitis is equal in men and women. But women and men with ulcerative colitis have respectively a 9.5 and 45.5 times greater risk of liver and gallbladder cancer, and 31 times the risk of primary sclerosing cholangitis, which are not influenced by medical or surgical treatment of ulcerative colitis. Overall cancer risk in patients with ulcerative colitis is 1.8 times that of the general population.
Following this reasoning and given the positive result of nicotine treatment in experimental models of DSS colitis (Ghia et al., 2006) , nicotine treatment might well be beneficial in ulcerative colitis. However, the clinical trials using nicotine for the treatment of ulcerative colitis have provided different results. A recent clinical trial includes the treatment of 104 patients with active UC with either 6 mg nicotine enemas or placebo enemas for 6 weeks in a randomized double-blind study . The enemas were well tolerated, but were not found to be efficacious for active ulcerative colitis. This study indicates that Clinical remission was achieved in 14 of 52 (27%) patients on active treatment and 14 of 43 (33%) patients on placebo (P ¼ 0.55). In 47 patients taking mesalamine only, active treatment conferred benefit that was not statistically significant; disease remission occurred in 9 of 25 patients on active therapy and 4 of 21 patients on placebo (P ¼ 0. . The patients in the nicotine group had a statistically significant greater improvement in the histological and global clinical score of colitis, including lower abdominal pain, stool frequency and fecal urgency. Seventeen of the 30 patients that finished the nicotine treatment had complete remissions, as compared with 9 of the 37 patients in the placebo group. Since the trial included patients who had never smoked, the tolerance and pharmacokinetics of transdermal nicotine was first studied in normal subjects who were lifelong nonsmokers. The nicotine doses were increased in a stepwise manner over a period of 5 days to minimize side effects. Three out of 12 nonsmoker subjects were intolerant to nicotine, but the remaining 9 tolerated doses of 15 and 25 mg/day. Most patients with ulcerative colitis also tolerated similar doses of nicotine given in stepwise increments, although many had side effects. Five out of 35 patients in the nicotine group withdrew treatment because of intolerable side effects. The most common side effects were similar in both groups including nausea, lightheadedness, headache, sleep disturbance and dizziness. The occurrence of side effects in the nicotine group was related to the patients' smoking history; they occurred in 10 of the 11 lifelong nonsmokers as compared with 13 of the 24 former smokers. There were no significant correlations between side effects and plasma nicotine or cotinine concentrations. The total mean dose in the nicotine group was 1776 mg, concentrations that were approximately 35% of the average for smokers. The cutoff point for distinguishing smokers from nonsmokers is 14 ng/ml. On average, each increase of 11 ng/ml in the plasma cotinine concentration reflects a nicotine intake of 1 mg (about one cigarette) in 24 h. During and after the trial, a7 as a pharmacological target for inflammationnone reported a craving for smoking, suggesting that addiction may depend on the sharp increases in plasma nicotine concentrations that follow smoking, which are unlike the steady release from transdermal patches.
The potential therapeutic effects of nicotine are likely due to the binding to nicotine receptors in the gut immune cells and inhibiting inflammatory mediators like TNF and IL-8 or, alternatively, by changing adherent surface mucus in the colon (Zijlstra et al., 1994; Thomas et al., 2005) . However, nicotine may be more effective in reducing the acute neuromotor symptoms of active colitis than in suppressing the underlying abnormality responsible for the relapsing nature of the condition (Thomas et al., 2005) . Indeed, a randomized, double-blind clinical trial involving 80 patients with ulcerative colitis in remission indicated that transdermal nicotine alone was no better than placebo in maintaining the remission of ulcerative colitis (Thomas et al., 2005) . The clinical and histological scores worsened over the 6 months of the study, and the number and the time course of the relapses were almost identical in the two groups. As compared with previous studies of acute colitis, this study presents several changes that may account for the clinical outcome. Transdermal nicotine was administered alone rather than in addition to a dose of mesalamine. Treatment began with a dose of only 2.5 mg, followed by a very slow buildup to a maintenance dose of 15 mg, instead of 25 mg. The patch was worn only during the day and removed at bedtime rather than being left on for 24 h. Although it is not possible to establish how any of these changes influenced the efficacy of treatment, the serum nicotine and cotinine concentrations of these patients were lower than expected. In other studies, the average daily intake of 15 mg of nicotine should produce cotinine concentrations of approximately 120 ng/ml; however, this study recorded concentrations of only 70 ng/ml. If future studies confirm nicotine to be ineffective as a maintenance therapy for ulcerative colitis, but effective for the active disease, then the situation is analogous to that of corticosteroids . Although corticosteroids have been shown repeatedly to be effective for acute colitis, they are of little value for the maintenance of clinical remission. Although nicotine doses were increased stepwise over a period of several days, the treatment with nicotine was still associated with side effects including nausea lightheadedness, headache, sleep disturbance and dizziness. These studies suggested that, in contrast to the outcome of epidemiological studies of smokers suffering from colitis, nicotine administration may not lead to better therapeutic ratios as compared to the treatment with corticosteroids, presumably due to side effects.
The use of specific a7 nicotinic agonists is expected to bear potential as a maintenance therapy for active ulcerative disease. Such selective nicotinic agonists were originally designed to mimic the cognitive effects of nicotine in patients with neurological disorders while avoiding the toxicity of nicotine. The most characterized specific a7 nAChR-agonists are GTS21 (Ulloa, 2005) . Among these, the most characterized is GTS-21, a partial a7 nAChR-agonist designed to compensate for loss of this receptor in the cerebral cortex and hippocampus of patients with Alzheimer's disease (Figure 4) . In vitro, GTS-21 can protect neurons against damage induced by amyloid peptides, suggesting that a7 nAChRs may have a protective neuronal role. GTS-21 is a partial agonist that affects other nicotinic receptors including a4b2-nAChRs (Kitagawa et al., 2003; Ulloa, 2005) . Treatment with GTS-21 produced beneficial effects in psychological and cognitive tests when given to healthy volunteers in clinical trials conducted by Taiho Pharmaceutical Co., Tokyo, Japan. However, GTS21 produced a limited therapeutic effect in clinical trials with Alzheimer's disease. Although the reasons for this effect remain unknown, some authors suggested that GTS21 may have limited capacity to cross the blood-brainbarrier. From an immunological perspective, this characteristic is an advantage to avoid potential secondary effects of GTS21 in the CNS. In contrast to nicotine, GTS21 has no effect on locomotor activity in mice or on dopamine turnover in rats indicating that it is less toxic than nicotine The anti-inflammatory potential of GTS21 was analyzed in experimental models of pancreatitis (van Westerloo et al., 2006). Surgical vagotomy or pretreatment with mecamylamine resulted in an enhanced severity of pancreatitis, induced by 12-h intraperitoneal injections of cerulean in mice. The number of neutrophils migrating to the pancreas was increased in these mice, as shown by myeloperoxidase content and intrapancreatic staining of neutrophils. Conversely, GTS-21 pretreatment strongly decreased the severity of pancreatitis. Of note, pancreatitis-associated pulmonary inflammation was independent of the integrity of the vagus nerve and nicotinic receptors. These results are in agreement with other studies indicating the vagus nerve has a very limited anti-inflammatory potential in the lungs (Borovikova et al., 2000).
Other nicotinic agonists used in experimental models of inflammation include CAP55, which was used to study the potential anti-inflammatory potential of nicotinic agonists in endothelial cells (Saeed et al., 2005) . CAP55 inhibited the LPS-induced production of TNF and TNF-induced production of chemokines in cultures of both human macrophages differentiated from peripheral blood mononuclear cells and microvascular endothelial cells (HUMVEC). In vitro, nicotine and CAP55 blocked TNF-induced adhesion molecule expression in HUMVEC and prevented monocyte and neutrophil adhesion to these cells. In the experimental carrageenan air pouch model, both vagus nerve stimulation and nicotinic agonists significantly blocked leukocyte migration through a mechanism dependent on nAChRs and inhibited by mecamylamine (Martin et al., 2004; Saeed et al., 2005) . These results are in agreement with previous studies indicating that nicotine enhances the angiogenic response to inflammation. Nicotine increased endothelial-cell growth and tube formation in vitro, and accelerated fibrovascular growth in vivo. In mouse models of hind-limb ischemia, lung cancer and atherosclerosis, nicotine increased capillary and lesion growth in association with an increase in lesion vascularity. Increased vascularization of the tumor tissue was associated with a higher tumor growth in the nicotine group. Treatment with nicotine caused higher serum levels of VEGF and the angiogenic effect was abrogated with a COX-2 inhibitor (Heeschen et al., 2001) . Although these studies indicated that nicotinic agonists can target endothelial cells in vitro, it is uncertain how the vagus nerve modulates the air pouch in the foot. According to the recent implication of the spleen in the anti-inflammatory potential of the vagus nerve , future studies are needed to determine whether the inhibition of the leukocyte migration in the carrageenan air pouch mode is due to the effect of vagus nerve on the foot or leukocyte differentiation in the spleen.
The therapeutic anti-inflammatory potential of nicotine in ulcerative colitis is not observed in other inflammatory bowel disorders. Treatment with nicotine induces no therapeutic effect on patients with Crohn's disease. Unlike ulcerative colitis, Crohn's disease is an inflammatory bowel disorder that is responsive to antibiotics such as Metronidazole and anti-TNF therapy. Obviously, these two inflammatory disorders have differential pathogenesis and a differential involvement of macrophage function. An alternative explanation for the disparate effect of nicotine on ulcerative colitis and Crohn's disease is that they might represent different levels of the cholinergic anti-inflammatory mechanism. Ulcerative colitis might be characterized by a defect in acetylcholine production that can be reversed by the administration of nicotine. However, Crohn's disease might be characterized by defects in the nicotinic receptor or signaling pathway that interfere with the potential of intestinal immune cells to respond to nicotine or acetylcholine. It is noteworthy that a similar mechanism might apply to different arthritic diseases. Smoking appears to confer Figure 4 Chemical structure of selective cholinergic agonists and antagonists. Nicotinic agonists specifically targeting the a7 nAChR have been developed. Acetylcholine (a) can signal through acetylcholine signals through either (c) muscarinic (G protein-coupled receptors) or (b) nicotinic (ligand-gated ion channels) receptors. These receptors are characterized by using selective pharmacological agonists and antagonists for nicotinic (nicotine vs mecamylamine) and muscarinic (muscarine vs atropine) receptors. Nicotine, a more selective and stable cholinergic agonist, is more efficient than acetylcholine as an anti-inflammatory pharmacological strategy. (d) The anti-inflammatory potential of nicotine appears to be mediated by the a7 nAChR, and recent studies are currently focused on designing selective a7-agonists as a antiinflammatory pharmacological strategy for the treatment of infectious and inflammatory disorders. some protection against osteoarthritis, but increases the risk of rheumatoid arthritis (Papadopoulos et al., 2005) . If specific mutations in the nAChR may prevent the activation of these receptors by acetylcholine or nicotine, future studies will be needed to determine the potential effect of allosteric enhancers, specific agonists able activate these receptors without binding to the ACh-binding site (Martin et al., 2004; Akk and Steinbach, 2005) . The most characteristic examples are physostigmine and galantamine (Reminyl; Janssen Pharmaceutica, Titusville, NJ, USA); both belong to a class of acetylcholinesterase inhibitors approved by the Food and Drug Administration for symptomatic treatment of schizophrenia and Alzheimer's disease. Their efficacy rests on enhancement of cholinergic signaling by inhibiting acetylcholinesterase and preventing acetylcholine degradation. However, the specificity of these compounds is questionable and its use has many neurotoxic side effects. Future studies are required to determine the anti-inflammatory potential of these compounds in immune cells and whether their effects are mediated by an allosteric regulation of nAChR.
Concluding remarks and future directions
The parasympathetic nervous system is a critical component of many pharmacological anti-inflammatory strategies against infectious and inflammatory disorders. One can distinguish two different types of anti-inflammatory compounds in which the efficacy may involve vagal nerve signaling. First, a group of compounds that either centrally or peripherally trigger vagal nerve activity including semapimod, CCK, leptin, melanocortin peptides, aspirin and other nonsteroidal anti-inflammatory drugs. This group is consistent with a previously unrecognized role of the vagus nerve in mediating the action of anti-inflammatory drugs and its pharmacological implications for the treatment of infectious and inflammatory disorders. A second group of anti-inflammatory compounds encompasses a variety of compounds, similar to acetylcholine and nicotinic agonists that are not dependent on an intact vagus nerve. Similar to the vagus nerve, specific nicotinic agonists can control systemic inflammation by regulating the production of proinflammatory cytokines in the spleen. However, unlike the vagus nerve, nicotinic agonists can induce an additional systemic effect and target other organs than the spleen. For instance, although vagus nerve has very limited antiinflammatory potential in the lungs, nicotine induces a significant anti-inflammatory effect in the lung. This effect of nicotine in the lung is especially relevant in smokers. A similar reasoning also applies to the implications of nicotine for the treatment of inflammatory bowel diseases. Nicotine induces a therapeutic anti-inflammatory potential in the gastrointestinal tract that may be useful for the treatment of ulcerative colitis. As described previously, the release of acetylcholine from the vagus nerve in the intestine or the enteric nervous system is expected to inhibit cytokine production by macrophages and alter DC function. Conversely, modification of macrophage function could trigger enhanced reactivity against intestinal bacterial antigens in the gastrointestinal tract.
The study of the expression of specific nicotinic receptors in different cell types and organs, and the development of selective nicotinic agonists is critical to develop novel pharmacological strategies against neurological, infectious and inflammatory disorders. This consideration is especially relevant to avoid side effects of nicotine in other cell types. A characteristic example is based on the inhibition of the NF-kB pathway by nicotine. NF-kB not only contributes to pathological inflammatory responses, but also protects parenchyma cells from cytotoxic reagents. One of the most characteristic examples is that IKKb-and p65RelA-knockout mice exhibit embryonic death resulting from extensive TNFmediated fetal hepatocyte apoptosis. Consistently, disruption of the TNF signaling, by removing either TNF or TNF-R1, prevents this hepatocyte apoptosis in RelaÀ/À mice, allowing embryonic development to proceed through to birth.
In vivo, inhibition of NF-kB after partial hepatectomy results in massive hepatocyte necrosis associated with impaired liver function and decreased survival. Moreover, treatment with anti-HMGB1 antibodies to prevent hepatic injury in response to ischemic insult is associated with enhanced activation of the NF-kB pathway. However, anti-HMGB1 antibodies abrogate the activation of NF-kB in HMGB1-challenged enterocytes and prevent intestinal derangements. In agreement with this reasoning, recent studies indicate that treatment with nicotine prevents systemic inflammation in healthy animals, but worsens the clinical outcome in splenectomized mice, probably by inhibiting the NF-kB in other organs including the liver. This doubly edged sword makes it challenging to predict the clinical outcome of nonspecific inhibition of NF-kB in human inflammatory diseases and injuries. Unless therapy is specifically targeted to specific immune and cytokine-producing cells, inhibition of NF-kB activity may not generate an overall beneficial effect, especially in tissue injuries such as acute lung injury or hepatic injury induced by ischemia/reperfusion. Future studies will have to determine whether a7 nAChR-agonists can control NF-kB activity in specific cytokine-producing cells avoiding collateral effects in other cell types.
INTRODUCTION
Cells of the innate immune system mediate inflammatory responses to pathogens and injury, activate coagulation, and initiate tissue repair. Activated macrophages, monocytes, and other cells release cytokines such as tumor necrosis factor (TNF), interleukin-1 (IL-1) and high mobility group box-1 (HMGB1), which act locally to amplify the inflammatory response and activate specific cellular responses. [1] [2] [3] [4] Cytokine production and release is tightly regulated, because inadequate responses result in immunodeficiency; excessive responses can become more dangerous than the activating stimulus, leading to hypotension, organ failure, and death. 5, 6 Multiple, redundant mechanisms have evolved to maintain immunological homeostasis and control local cytokine production; in the majority of cases, the cytokine response is locally constrained, and systemic toxicity is avoided. Locally acting anti-inflammatory mediators including IL-10, spermine, and prostaglandin E 2 (PGE 2 ) attenuate macrophage activation and suppress cytokine production. 7 Centrally derived neuropeptides such as ACTH, a-MSH and glucocorticoids, released into the circulation by the central nervous system (CNS) in response to infection or injury, also inhibit local cytokine production. [8] [9] [10] We recently described a neural anti-inflammatory mechanism that inhibits local pro-inflammatory cytokine production, termed 'the cholinergic anti-inflammatory pathway' (Fig. 1) . [11] [12] [13] Efferent activity in the vagus nerve releases acetylcholine in tissues, which binds specifically to nicotinic acetylcholine a7 subunit receptors on macrophages that inhibit endotoxininduced pro-inflammatory cytokine release. This has opened new avenues for potential development of novel agents that can modulate cytokine activity to therapeutic advantage. 14, 15 BACKGROUND During early studies, we observed that the anti-inflammatory action of the tetravalent guanylhydrazone CNI-1493, we observed that this compound prevents endotoxin-induced shock and inhibits TNF synthesis; in vagus nerve could suppress the systemic inflammatory response to endotoxin, we performed bilateral cervical vagotomy on adult male Lewis rats and specifically applied constant voltage to the distal end of the transected vagus nerve. Electrical stimulation of the vagus nerve significantly attenuated TNF serum levels, whereas vagotomy without stimulation significantly increased peak serum TNF levels as compared to shamoperated controls (Table 1) . 11, 12 Electrical stimulation of the intact vagus nerve also protected against endotoxininduced shock. 11, 12, 20 The protective effects of electrical vagus nerve stimulation were independent of vagus nerve laterality at the level of the cervical vagus nerve, because stimulation of either the left or right cervical vagus nerve elicited equivalent suppression of TNF. 12 Sham-stimulated animals, which underwent similar surgical procedures but did not receive electrical vagus nerve stimulation, failed to mount a tachycardic response to endotoxin-induced hypotension, while electrically stimulated animals maintained adequate blood pressure and developed tachycardia. 11, 12, 23 To determine whether inhibition of systemic proinflammatory cytokine responses by vagus nerve stimulation could be extended to other models of systemic inflammation that are independent of endotoxin, the vagus nerve was electrically stimulated in a standardized model of ischemia-reperfusion injury in rats subjected to aortic occlusion. 24 Ischemia-reperfusion led to significant increases of TNF in serum, heart, and liver; each of these were significantly inhibited when vagus nerve stimulation preceded application of a suprarenal aortic clamp. In addition to suppressing cytokine release, vagus nerve stimulation also prevented the development of ischemia-reperfusion-induced shock. 24 
RECEPTORS

Identification of macrophage nicotinic acetylcholine a7 receptors
To determine if the anti-inflammatory activity of the vagus nerve was mediated by acetylcholine, the principal neurotransmitter of the vagus nerve, primary human macrophage cultures were stimulated with endotoxin in the presence of acetylcholine. Acetylcholine inhibited the release of pro-inflammatory cytokines including TNF, IL-1, IL-18 and IL-6 in a dose-dependent manner ( Table 2) . Acetylcholine mediates its anti-inflammatory effects at a post-transcriptional level, because acetylcholine treatment reduced the level of TNF protein, but not mRNA expression.
11
Peripheral blood mononuclear cells express both nicotinic and muscarinic acetylcholine receptors. [25] [26] [27] To identify the receptor involved in acetylcholine-mediated inhibition of TNF, we measured TNF levels of endotoxin-stimulated macrophage cultures in the presence of either muscarine or nicotine. Nicotine dose-dependently suppressed TNF release in concentrations lower than those required for acetylcholine (EC 50 = 8.3 ± 7.1 nM and 20.2 ± 8.7 nM, respectively; Table 2 ); muscarine also inhibited TNF release, but required significantly higher concentrations than either nicotine or acetylcholine (EC 50 = 42.4 ± 18.6 mM). 11 Addition of the nicotinic antagonist a-bungarotoxin, a peptide that specifically binds a subset of nicotinic cholinergic receptors with high affinity, restored TNF release in a dose-dependent manner, indicating that the inhibitory effect of acetylcholine on endotoxin-induced responses is mediated primarily by Neural inhibition of inflammation: the cholinergic anti-inflammatory pathway 411 Table 1 . Vagus nerve stimulation protects against endotoxemia a-bungarotoxin-sensitive, nicotinic acetylcholine receptors. FITC-labeled a-bungarotoxin staining of macrophage cultures revealed distinct clusters of receptors expressed on the cell surface, reminiscent of staining patterns observed on neuronal cells; this staining pattern was inhibited by pre-incubation of the cells with nicotine. 13 Three a-bungarotoxin-binding nicotinic receptor subunits are known in human cells: a1, a7, and a9. a1 forms heteropentameric nicotinic receptors, together with other acetylcholine receptor subunits, while a7 and a9 each form homopentameric nicotinic receptors. RT-PCR analysis showed that both a1 and a7, but not a9, mRNA is expressed in human macrophages. 13 Western blotting revealed high expression levels of the a7 subunit protein; this result was confirmed in pull-down assays using abungarotoxin-conjugated beads, with proteins prepared from human macrophages or rat pheochromocytoma cells (which are known to express a7). In order to determine if the nicotinic acetylcholine receptor a7 subunit is required for cholinergic inhibition of TNF release, macrophages were exposed to antisense oligonucleotides specific to a7. In the presence of a7 antisense oligonucleotides, nicotine failed to decrease TNF release significantly. 13 The physiological relevance of the nicotinic acetylcholine receptor a7 subunit to mediating the cholinergic anti-inflammatory pathway was assessed in mice rendered deficient in the a7 gene by experimental knock-out technology. When exposed to endotoxin, a7-deficient mice produce significantly more TNF, IL-1, and other cytokines than wild-type litter-mates (Table 3 ). Electrical stimulation protocols that effectively attenuate systemic inflammatory responses to endotoxin in wild-type mice are ineffective in a7-deficient mice, demonstrating that the nicotinic acetylcholine receptor a7 subunit is required for the activity of the cholinergic anti-inflammatory pathway (Table 4) . 13 
IMPLICATIONS AND PERSPECTIVES
Our recent findings demonstrate that the cholinergic anti-inflammatory pathway directly regulates the systemic pro-inflammatory cytokine response to endotoxin and other inflammatory stimuli. This neural mechanism represents a previously unknown endogenous pathway that can suppress the lethal effects of biological toxins, with a much shorter response time than humoral antiinflammatory pathways. The identification of the physiological mechanism of action of the cholinergic anti-inflammatory pathway has wide-spread therapeutic implications for the treatment of inflammatory conditions.
14 Like CNI-1493, which functions as a pharmacological vagus nerve stimulator, it is likely that other compounds may function as centrally-acting vagus nerve stimulators to suppress systemic pro-inflammatory cytokine responses. Electrical stimulation of the vagus nerve using devices similar to those already used for epilepsy may prove to have anti-inflammatory activity in humans. Locally-acting cholinergic agonists such as nicotine, which directly bind acetylcholine receptors on tissue-resident macrophages and other cells of the innate immune system, may represent a third method of activating the cholinergic anti-inflammatory pathway. For example, nicotine has been used to treat patients with ulcerative colitis, a condition associated with excessive pro-inflammatory cytokine production in the gastrointestinal mucosa. [28] [29] [30] Although the mechanism of action of nicotine in ulcerative colitis is unknown, it is interesting to consider the potential role of nicotinic-type cholinergic receptors in this disease.
Autonomic dysfunction has been associated with inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and sepsis; whether this dysfunction causes or results from the inflammatory component of these diseases is now 412 Czura, Friedman, Tracey Table 3 . The nicotinic acetylcholine receptor a7 subunit is an essential regulator of inflammation in vivo Mice deficient in the nicotinic acetylcholine receptor a7 subunit (a7 knock out) produce significantly higher levels of pro-inflammatory cytokines in response to endotoxin than litter-mate controls (wild-type). Cytokine levels measured 90 min after LPS infusion, and presented as ng/g protein (tissue samples) or pg/ml (serum samples). Adapted from Wang et al. 13 Data presented as mean ± SEM; *P = 0.05 versus wild-type. Vagus nerve stimulation attenuates endotoxin-induced systemic TNF release in wild-type mice, but fails to protect a7-deficient mice (a7 knock out). Sham-stimulated animals (Sham) received a lethal dose of LPS, and had vagus nerves exposed but not simulated; other animals received electrical stimulation of intact cervical vagus nerve (VNS). TNF levels measured 2 h after LPS infusion, and presented as pg/ml. Adapted from Wang et al. 13 Data presented as mean ± SEM; *P = 0.05 versus sham wildtype. less clear. 14, 31 If vagus nerve stimulation by either electrical or pharmacological means suppresses the excess TNF response, it may be possible to treat these disorders through rational modulation of the vagus nerve. Support for this approach is found by considering that anti-TNF antibodies are clinically useful in treating Crohn's disease and rheumatoid arthritis, and additional indications are under study. Acupuncture has been used previously to modulate vagus activity and influence bowel function, gastric acidity, and heart rate. 32, 33 Hypnosis and meditation may inhibit immediate and delayed-type hypersensitivity responses through cholinergic anti-inflammatory pathway stimulation. 34, 35 Patients may also be trained to increase parasympathetic (vagus nerve) tone with biofeedback, suggesting another potential mechanism to utilize the cholinergic anti-inflammatory pathway to modulate diseases of excess pro-inflammatory cytokine synthesis.
